Patent Application
20220074077
The present invention relates to a modified fibroin fiber.
Fibroin is a kind of fibrous protein and contains up to 90% of glycine, alanine, and serine residues leading to formation of a β-pleated sheet (Non Patent Literature 1). Proteins (silk proteins, hornet silk proteins, and spider silk proteins) and the like constituting a yarn produced by insects and spiders are known as fibroin.
A fibroin fiber obtained by spinning fibroin has the property of shrinking when being in contact with water (for example, immersed in water or hot water, exposed to a high humidity environment, or the like). This property causes various problems in a manufacturing process and productization, and also affects a product made using the fibroin fiber.
As a shrink-proof method for preventing shrinkage of a product, for example, a method of shrink-proofing a silk fabric, in which a scoured silk fabric formed of a highly twisted yarn is immersed in water, another solvent, or a mixed system thereof in a tension state, and the silk fabric is heated for a predetermined time (Patent Literature 1), a method of fixing a shape of an animal fiber product, in which an animal fiber product formed in a required shape is subjected to a treatment of bringing the fiber product into contact with a high-pressure saturated water vapor at 120 to 200° C. to fix the shape of the fiber product during the water vapor treatment (Patent Literature 2), and the like are reported.
The shrink-proof method disclosed in Patent Literatures 1 and 2 is a shrink-proof method for a fiber product, and it is difficult to apply the shrink-proof method as it is to prevent a fiber, which is a material, from being shrunk. These methods are not versatile for various products produced by using a fibroin fiber. If the shrinkage of the fibroin fiber itself can be reduced regardless of using such a shrink-proof method, it is industrially very useful and versatile.
An object of the present invention is to provide a fibroin fiber with reduced shrinkage itself.
The present inventors have conducted intensive studies in order to solve the above problems. As a result, the present inventors found that shrinkage of a modified fibroin fiber by contact with water is reduced by adjusting a fiber diameter of the modified fibroin fiber or a raw material fiber of the modified fibroin fiber. The present invention is based on such novel findings.
That is, the present invention relates to, for example, each of the following inventions.
[1]
A modified fibroin fiber having a shrinkage history of being irreversibly shrunk after spinning, the modified fibroin fiber containing modified fibroin, wherein a fiber diameter of a raw material fiber before being irreversibly shrunk exceeds 25 μm.
[2]
The modified fibroin fiber according to [1], wherein the shrinkage history is a shrinkage history of being irreversibly shrunk by bringing the raw material fiber into contact with water or a shrinkage history of being irreversibly shrunk by heating and relaxing the raw material fiber.
[3]
The modified fibroin fiber according to [1] or [2], wherein there is substantially no residual stress generated by drawing during a spinning process.
[4]
The modified fibroin fiber according to any one of [1] to [3], wherein a shrinkage rate is 3.3% or less, the shrinkage rate being defined by the following Equation (1):
Shrinkage rate (%)=(1−(length of modified fibroin fiber when dried from wet state/length of modified fibroin fiber when in wet state))×100.
[5]
The modified fibroin fiber according to any one of [1] to [4], wherein the modified fibroin is modified spider silk fibroin.
[6]
The modified fibroin fiber according to any one of [1] to [5], wherein the modified fibroin is hydrophobic-modified spider silk fibroin.
[7]
The modified fibroin fiber according to any one of [1] to [6], wherein the modified fibroin fiber has a fiber diameter of less than ±20% of the fiber diameter of the raw material fiber before being irreversibly shrunk.
[8]
The modified fibroin fiber according to any one of [1] to [7], wherein a sectional shape is a circular shape or an elliptical shape.
[9]
The modified fibroin fiber according to any one of [1] to [8], wherein the modified fibroin fiber has a matte-toned appearance.
[10]
A product including the modified fibroin fiber according to any one of [1] to [9].
[11]
The product according to [10], wherein the product is selected from the group consisting of a fiber, a yarn, a fabric, a knitted fabric, a braided fabric, a non-woven fabric, a paper, and cotton.
[12]
A production method of a modified fibroin fiber, including a shrinking step of irreversibly shrinking a raw material fiber,
wherein the raw material fiber contains modified fibroin, and
before the shrinking step, the raw material fiber has a fiber diameter of more than 25 μm.
[13]
The production method according to [12], wherein in the shrinking step, the raw material fiber is irreversibly shrunk by bringing the raw material fiber into contact with water, or the raw material fiber is irreversibly shrunk by heating and relaxing the raw material fiber.
[14]
The production method according to [12] or [13], wherein in the shrinking step, the raw material fiber is substantially completely free of a residual stress generated by drawing during a spinning process.
[15]
The production method according to any one of [12] to [14], wherein the modified fibroin is modified spider silk fibroin.
[16]
The production method according to any one of [12] to [15], wherein the modified fibroin is hydrophobic-modified spider silk fibroin.
[17]
A modified fibroin fiber containing modified fibroin, wherein the modified fibroin fiber has a fiber diameter of more than 25 μm, and a shrinkage rate is 3.3% or less, the shrinkage rate being defined by the following Equation (1):
Shrinkage rate (%)=(1−(length of modified fibroin fiber when dried from wet state/length of modified fibroin fiber when in wet state))×100.
[18]
The modified fibroin fiber according to [17], wherein the modified fibroin fiber has a shrinkage history of being irreversibly shrunk after spinning.
[19]
The modified fibroin fiber according to [18], wherein the modified fibroin fiber has a fiber diameter of less than ±20% of a fiber diameter of a raw material fiber before being irreversibly shrunk.
[20]
The modified fibroin fiber according to [18] or [19], wherein the shrinkage history is a shrinkage history of being irreversibly shrunk by bringing the raw material fiber into contact with water or a shrinkage history of being irreversibly shrunk by heating and relaxing the raw material fiber.
[21]
The modified fibroin fiber according to any one of [17] to [20], wherein there is substantially no residual stress generated by drawing during a spinning process.
[22]
The modified fibroin fiber according to any one of [17] to [21], wherein the modified fibroin is modified spider silk fibroin.
[23]
The modified fibroin fiber according to any one of [17] to [22], wherein the modified fibroin is hydrophobic-modified spider silk fibroin.
[24]
The modified fibroin fiber according to any one of [17] to [23], wherein a sectional shape is a circular shape or an elliptical shape.
[25]
The modified fibroin fiber according to any one of [17] to [24], wherein the modified fibroin fiber has a matte-toned appearance.
[26]
A product including the modified fibroin fiber according to any one of [17] to [25].
[27]
The product according to [26], wherein the product is selected from the group consisting of a fiber, a yarn, a fabric, a knitted fabric, a braided fabric, a non-woven fabric, a paper, and cotton.
According to the present invention, it is possible to provide a fibroin fiber with reduced shrinkage itself.
Hereinafter, embodiments of the present invention will be described in detail. However, the present invention is not limited to the following embodiments.
[Modified Fibroin]
Modified fibroin according to the present embodiment is a protein containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif. An amino acid sequence (N-terminal sequence and C-terminal sequence) may be further added to either or both of the N-terminus and the C-terminus of the domain sequence of the modified fibroin. The N-terminal sequence and the C-terminal sequence, although not limited thereto, are typically regions that do not have repetitions of amino acid motifs characteristic of fibroin and consist of amino acids of about 100 residues. In the present embodiment, as the modified fibroin, modified spider silk fibroin is preferably used in terms of heat retaining properties, hygroscopic and exothermic properties, and/or flame retardancy.
The term “modified fibroin” in the present specification refers to artificially produced fibroin (artificial fibroin). The modified fibroin may be fibroin in which a domain sequence is different from an amino acid sequence of naturally derived fibroin or may be fibroin in which a domain sequence is the same as an amino acid sequence of naturally derived fibroin. The “naturally derived fibroin” referred to in the present specification is also a protein containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif.
The “modified fibroin” may be fibroin obtained by using an amino acid sequence of naturally derived fibroin as it is, fibroin in which an amino acid sequence is modified based on an amino acid sequence of naturally derived fibroin (for example, fibroin in which an amino acid sequence is modified by modifying a cloned gene sequence of naturally derived fibroin), or fibroin artificially designed and synthesized independently of naturally derived fibroin (for example, fibroin having a desired amino acid sequence by chemically synthesizing a nucleic acid encoding a designed amino acid sequence).
In the present specification, the term “domain sequence” refers to an amino acid sequence which produces a crystalline region (typically, corresponding to an (A)n motif of an amino acid sequence) and an amorphous region (typically, corresponding to REP of an amino acid sequence) specific to fibroin, and refers to an amino acid sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif. Here, the (A)n motif represents an amino acid sequence mainly consisting of alanine residues, and the number of amino acid residues in the (A)n motif is 2 to 27. The number of amino acid residues in the (A)n motif may be an integer of 2 to 20, 4 to 27, 4 to 20, 8 to 20, 10 to 20, 4 to 16, 8 to 16, or 10 to 16. In addition, a proportion of the number of alanine residues to a total number of amino acid residues in the (A)n motif may be 40% or more, and may also be 60% or more, 70% or more, 80% or more, 83% or more, 85% or more, 86% or more, 90% or more, 95% or more, or 100% (which means that the (A)n motif consists of only alanine residues). At least a plurality of seven (A)n motifs present in the domain sequence may consist of only alanine residues. The REP represents an amino acid sequence consisting of 2 to 200 amino acid residues. The REP may be an amino acid sequence consisting of 10 to 200 amino acid residues or may be an amino acid sequence consisting of 10 to 40, 10 to 60, 10 to 80, 10 to 100, 10 to 120, 10 to 140, 10 to 160, or 10 to 180 amino acid residues. m represents an integer of 2 to 300, and may be an integer of 8 to 300, 10 to 300, 20 to 300, 40 to 300, 60 to 300, 80 to 300, 10 to 200, 20 to 200, 20 to 180, 20 to 160, 20 to 140, or 20 to 120. The plurality of (A)n motifs may be the same amino acid sequences or different amino acid sequences. A plurality of REP's may be the same amino acid sequences or different amino acid sequences.
The modified fibroin according to the present embodiment can be obtained by, for example, performing modification of an amino acid sequence corresponding to substitution, deletion, insertion, and/or addition of one or a plurality of amino acid residues with respect to a cloned gene sequence of naturally derived fibroin. Substitution, deletion, insertion, and/or addition of the amino acid residues can be performed by methods well known to those skilled in the art, such as site-directed mutagenesis. Specifically, it can be performed according to a method described in literatures such as Nucleic Acid Res. 10, 6487 (1982) and Methods in Enzymology, 100, 448 (1983).
The naturally derived fibroin is a protein containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif, and a specific example thereof can include fibroin produced by insects or spiders.
Examples of the fibroin produced by insects can include silk proteins produced by silkworms such as Bombyx mori, Bombyx mandarina, Antheraea yamamai, Anteraea pernyi, Eriogyna pyretorum, Pilosamia Cynthia ricini, Samia cynthia, Caligura japonica, Antheraea mylitta, and Antheraea assama, and hornet silk proteins discharged from larvae of Vespa simillima xanthoptera.
A more specific example of the fibroin produced by insects can include a silkworm fibroin L chain (GenBank Accession No. M76430 (base sequence) and AAA27840.1 (amino acid sequence)).
Examples of the fibroin produced by spiders can include spider silk proteins produced by spiders belonging to the genus Araneus such as Araneus ventricosus, Araneus diadematus, Araneus quadratus, Araneus pentagrammicus, and Araneus nojimai, spiders belonging to the genus Neoscona such as Neoscona scylla, Neoscona nautica, Neoscona adianta, and Neoscona scylloides, spiders belonging to the genus Pronus such as Pronouns minutes, spiders belonging to the genus Cyrtarachne such as Cyrtarachne bufo and Cyrtarachne inaequalis, spiders belonging to the genus Gasteracantha such as Gasteracantha kuhli and Gasteracantha mammosa, spiders belonging to the genus Ordgarius such as Ordgarius hobsoni and Ordgarius sexspinosus, spiders belonging to the genus Argiope such as Argiope amoena, Argiope minuta, and Argiope bruennichi, spiders belonging to the genus Arachnura such as Arachnura logio, spiders belonging to the genus Acusilas such as Acusilas coccineus, spiders belonging to the genus Cytophora such as Cyrtophora moluccensis, Cyrtophora exanthematica, and Cyrtophora unicolor, spiders belonging to the genus Poltys such as Poltys illepidus, spiders belonging to the genus Cyclosa such as Cyclosa octotuberculata, Cyclosa sedeculata, Cyclosa vallata, and Cyclosa atrata, and spiders belonging to the genus Chorizopes such as Chorizopes nipponicus, and spider silk proteins produced by spiders belonging to the genus Tetragnatha such as Tetragnatha praedonia, Tetragnatha maxillosa, Tetragnatha extensa, and Tetragnatha squamata, spiders belonging to the genus Leucauge such as Leucauge magnifica, Leucauge blanda, and Leucauge subblanda, spiders belonging to the genus Nephila such as Nephila clavata and Nephila pilipes, spiders belonging to the genus Menosira such as Menosira ornata, spiders belonging to the genus Dyschiriognatha such as Dyschiriognatha tenera, spiders belonging to the genus Latrodectus such as Latrodectus mactans, Latrodectus hasseltii, Latrodectus geometricus, and Latrodectus tredecimguttatus, and spiders belonging to the family Tetragnathidae such as spiders belonging to the genus Euprosthenops. Examples of the spider silk protein can include traction fiber proteins such as MaSp (MaSp1 and MaSp2) and ADF (ADF3 and ADF4), and MiSp (MiSp1 and MiSp2).
More specific examples of the spider silk protein produced by spiders can include fibroin-3 (adf-3) [derived from Araneus diadematus] (GenBank Accession No. AAC47010 (amino acid sequence), U47855 (base sequence)), fibroin-4 (adf-4) [derived from Araneus diadematus] (GenBank Accession No. AAC47011 (amino acid sequence), U47856 (base sequence)), dragline silk protein spidroin 1 [derived from Nephila clavipes] (GenBank Accession No. AAC04504 (amino acid sequence), U37520 (base sequence)), major ampullate spidroin 1 [derived from Latrodectus hesperus] (GenBank Accession No. ABR68856 (amino acid sequence), EF595246 (base sequence)), dragline silk protein spidroin 2 [derived from Nephila clavata] (GenBank Accession No. AAL32472 (amino acid sequence), AF441245 (base sequence)), major ampullate spidroin 1 [derived from Euprosthenops australis] (GenBank Accession No. CAJ00428 (amino acid sequence), AJ973155 (base sequence)), major ampullate spidroin 2 [Euprosthenops australis] (GenBank Accession No. CAM32249.1 (amino acid sequence), AM490169 (base sequence)), minor ampullate silk protein 1 [Nephila clavipes] (GenBank Accession No. AAC14589.1 (amino acid sequence)), minor ampullate silk protein 2 [Nephila clavipes] (GenBank Accession No. AAC14591.1 (amino acid sequence)), and minor ampullate spidroin-like protein [Nephilengys cruentata] (GenBank Accession No. ABR37278.1 (amino acid sequence)).
A still more specific example of the naturally derived fibroin can include fibroin with sequence information registered in NCBI GenBank. For example, it can be confirmed by extracting sequences in which spidroin, ampullate, fibroin, “silk and polypeptide”, or “silk and protein” is described as a keyword in DEFINITION among sequences containing INV as DIVISION among sequence information registered in NCBI GenBank, sequences in which a specific character string of products is described from CDS, or sequences in which a specific character string is described from SOURCE to TISSUE TYPE.
The modified fibroin according to the present embodiment may be modified silk fibroin (in which an amino acid sequence of silk protein produced by silkworm is modified), or may be modified spider silk fibroin (in which an amino acid sequence of a spider silk protein produced by spiders is modified). Modified spider silk fibroin is preferred as the modified fibroin.
Specific examples of the modified fibroin can include modified fibroin derived from a major dragline silk protein produced in a major ampullate gland of a spider (first modified fibroin), modified fibroin containing a domain sequence in which a content of glycine residues is reduced (second modified fibroin), modified fibroin containing a domain sequence in which a content of an (A)n motif is reduced (third modified fibroin), modified fibroin containing a domain sequence in which a content of glycine residues and a content of an (A)n motif are reduced (fourth modified fibroin), modified fibroin containing a domain sequence including a region locally having a high hydropathy index (fifth modified fibroin), and modified fibroin containing a domain sequence in which a content of glutamine residues is reduced (sixth modified fibroin).
An example of the first modified fibroin can include a protein containing a domain sequence represented by Formula 1: [(A)n motif-REP]m. In the first modified fibroin, the number of amino acid residues in the (A)n motif is preferably an integer of 3 to 20, more preferably an integer of 4 to 20, still more preferably an integer of 8 to 20, still more preferably an integer of 10 to 20, still more preferably an integer of 4 to 16, particularly preferably an integer of 8 to 16, and most preferably an integer of 10 to 16. In the first modified fibroin, the number of amino acid residues constituting REP in Formula 1 is preferably 10 to 200 residues, more preferably 10 to 150 residues, and still more preferably 20 to 100 residues, and still more preferably 20 to 75 residues. In the first modified fibroin, a total number of glycine residues, serine residues, and alanine residues contained in the amino acid sequence represented by Formula 1: [(A)n motif-REP]m is preferably 40% or more, more preferably 60% or more, and still more preferably 70% or more, with respect to a total number of amino acid residues.
The first modified fibroin may be a polypeptide having an amino acid sequence unit represented by Formula 1: [(A)n motif-REP]m, and having a C-terminal sequence which is an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3 or a C-terminal sequence which is an amino acid sequence having 90% or more homology with the amino acid sequence set forth in any one of SEQ ID NOs: 1 to 3.
The amino acid sequence set forth in SEQ ID NO: 1 is identical to an amino acid sequence consisting of 50 amino acid residues at the C-terminus of an amino acid sequence of ADF3 (GI:1263287, NCBI), the amino acid sequence set forth in SEQ ID NO: 2 is identical to an amino acid sequence obtained by removing 20 residues from the C-terminus of the amino acid sequence set forth in SEQ ID NO: 1, and the amino acid sequence set forth in SEQ ID NO: 3 is identical to an amino acid sequence obtained by removing 29 residues from the C-terminus of the amino acid sequence set forth in SEQ ID NO: 1.
A more specific example of the first modified fibroin can include modified fibroin having an amino acid sequence set forth in (1-i) SEQ ID NO: 4 (recombinant spider silk protein ADF3KaiLargeNRSH1), or (1-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in (1-i) SEQ ID NO: 4. The sequence identity is preferably 95% or more.
The amino acid sequence set forth in SEQ ID NO: 4 is an amino acid sequence obtained by approximately doubling first to thirteenth repeating regions and performing mutation so that translation is terminated at the 1154th amino acid residue in an amino acid sequence obtained by adding the amino acid sequence (SEQ ID NO: 5) of ADF3 consisting of a start codon, a His10 tag, and a recognition site for HRV3C protease (human rhinovirus 3C protease) to the N-terminus thereof. The C-terminal amino acid sequence of the amino acid sequence set forth in SEQ ID NO: 4 is identical to the amino acid sequence set forth in SEQ ID NO: 3.
The modified fibroin of (1-i) may consist of the amino acid sequence set forth in SEQ ID NO: 4.
The domain sequence of the second modified fibroin has an amino acid sequence in which a content of glycine residues is reduced, as compared with the naturally derived fibroin. It can be said that the second modified fibroin has an amino acid sequence corresponding to an amino acid sequence in which at least one or a plurality of glycine residues in REP are substituted with another amino acid residue, as compared with the naturally derived fibroin.
The domain sequence of the second modified fibroin may have an amino acid sequence corresponding to an amino acid sequence in which one glycine residue in at least one or the plurality of motif sequences is substituted with another amino acid residue, in at least one motif sequence selected from GGX and GPGXX (where G represents a glycine residue, P represents a proline residue, and X represents an amino acid residue other than glycine) in REP, as compared with the naturally derived fibroin.
In the second modified fibroin, a proportion of the motif sequences in which the above-described glycine residue is substituted with another amino acid residue may be 10% or more with respect to the entire motif sequences.
The second modified fibroin may contain a domain sequence represented by Formula 1: [(A)n motif-REP]m and may have an amino acid sequence in which z/w is 30% or more, 40% or more, 50% or more, or 50.9% or more, in which a total number of amino acid residues in an amino acid sequence consisting of XGX (where X represents an amino acid residue other than glycine) contained in all REP's in a sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence is z, and a total number of amino acid residues in a sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence is w.
The number of alanine residues with respect to the total number of amino acid residues in the (A)n motif is 83% or more, preferably 86% or more, more preferably 90% or more, still more preferably 95% or more, and still more preferably 100% (which means that the (A)n motif consists of only alanine residues).
In the second modified fibroin, a content ratio of the amino acid sequence consisting of XGX is preferably increased by substituting one glycine residue in a GGX motif with another amino acid residue. In the second modified fibroin, a content ratio of an amino acid sequence consisting of GGX in the domain sequence is preferably 30% or less, more preferably 20% or less, still more preferably 10% or less, still more preferably 6% or less, still more preferably 4% or less, and particularly preferably 2% or less. The content ratio of the amino acid sequence consisting of GGX in the domain sequence can be calculated by the same method as the following calculation method of a content ratio (z/w) of the amino acid sequence consisting of XGX.
The calculation method of z/w will be described in more detail. First, the amino acid sequence consisting of XGX is extracted from all the REP's contained in the sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence in the fibroin containing the domain sequence represented by Formula 1: [(A)n motif-REP]m (modified fibroin or naturally derived fibroin). A total number of amino acid residues consisting of XGX is z. For example, in a case where 50 amino acid sequences consisting of XGX are extracted (there is no overlap), z is 50×3=150. In addition, for example, in a case where two Xs (central X) contained in XGX are present as in a case of an amino acid sequence consisting of XGXGX, it is calculated by subtracting the overlapping portion (in the case of XGXGX, z is 5 amino acid residues). w is a total number of amino acid residues contained in the sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence. For example, in the case of the domain sequence illustrated in
Here, z/w in the naturally derived fibroin will be described. First, as described above, 663 types of fibroins (415 types of fibroins derived from spiders among them) were extracted by confirming fibroins with amino acid sequence information registered in NCBI GenBank by an exemplified method. z/w was calculated by the above-described calculation method from the amino acid sequences of the naturally derived fibroins which contain a domain sequence represented by Formula 1: [(A)n motif-REP]m and in which the content ratio of the amino acid sequence consisting of GGX in the fibroin is 6% or less, among all the extracted fibroins. As a result, z/w in each of the naturally derived fibroins is less than 50.9% (highest, 50.86%).
In the second modified fibroin, z/w is preferably 50.9% or more, more preferably 56.1% or more, still more preferably 58.7% or more, still more preferably 70% or more, and still more preferably 80% or more. An upper limit of z/w is not particularly limited, but may be, for example, 95% or less.
The second modified fibroin can be obtained by, for example, substituting and modifying at least a part of a base sequence encoding a glycine residue from a cloned gene sequence of naturally derived fibroin so as to encode another amino acid residue. In this case, one glycine residue in a GGX motif or a GPGXX motif may be selected as the glycine residue to be modified, and substitution may be performed so that z/w is 50.9% or more. In addition, the second modified fibroin can also be obtained by, for example, designing an amino acid sequence satisfying each of the above aspects from the amino acid sequence of the naturally derived fibroin, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence. In any case, in addition to the modification corresponding to substitution of a glycine residue in the REP with another amino acid residue from the amino acid sequence of the naturally derived fibroin, modification of the amino acid sequence corresponding to substitution, deletion, insertion, and/or addition of one or a plurality of amino acid residues may be performed.
The above-described another amino acid residue is not particularly limited as long as it is an amino acid residue other than a glycine residue, but it is preferably a hydrophobic amino acid residue such as a valine (V) residue, a leucine (L) residue, an isoleucine (I) residue, a methionine (M) residue, a proline (P) residue, a phenylalanine (F) residue, or a tryptophan (W) residue, or a hydrophilic amino acid residue such as a glutamine (Q) residue, an asparagine (N) residue, a serine (S) residue, a lysine (K) residue, or a glutamic acid (E) residue, more preferably a valine (V) residue, a leucine (L) residue, an isoleucine (I) residue, a phenylalanine (F) residue, or a glutamine (Q) residue, and still more preferably a glutamine (Q) residue.
A more specific example of the second modified fibroin can include a modified fibroin having (2-i) an amino acid sequence set forth in SEQ ID NO: 6 (Met-PRT380), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), or SEQ ID NO: 9 (Met-PRT799), or (2-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
The modified fibroin of (2-i) will be described. The amino acid sequence set forth in SEQ ID NO: 6 is obtained by substituting GQX for all GGXs in REP of the amino acid sequence set forth in SEQ ID NO: 10 (Met-PRT313) corresponding to the naturally derived fibroin. The amino acid sequence set forth in SEQ ID NO: 7 is obtained by deleting every other two (A)n motifs from the N-terminus to the C-terminus from the amino acid sequence set forth in SEQ ID NO: 6 and further inserting one [(A)n motif-REP] before the C-terminal sequence. The amino acid sequence set forth in SEQ ID NO: 8 is obtained by inserting two alanine residues at the C-terminus of each (A)n motif of the amino acid sequence set forth in SEQ ID NO: 7 and further substituting a part of glutamine (Q) residues with a serine (S) residue to delete a part of amino acids at the C-terminus so as to be almost the same as a molecular weight of SEQ ID NO: 7. The amino acid sequence set forth in SEQ ID NO: 9 is an amino acid sequence obtained by adding a predetermined hinge sequence and a His tag sequence to the C-terminus of a sequence obtained by repeating a region of 20 domain sequences (where several amino acid residues on the C-terminal side of the region are substituted) present in the amino acid sequence set forth in SEQ ID NO: 7 four times.
A value of z/w in the amino acid sequence set forth in SEQ ID NO: 10 (corresponding to naturally derived fibroin) is 46.8%. The values of z/w in the amino acid sequence set forth in SEQ ID NO: 6, the amino acid sequence set forth in SEQ ID NO: 7, the amino acid sequence set forth in SEQ ID NO: 8, and the amino acid sequence set forth in SEQ ID NO: 9 are 58.7%, 70.1%, 66.1%, and 70.0%, respectively. In addition, the values of x/y in the amino acid sequences set forth in SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9 at a Giza ratio (described below) of 1:1.8 to 11.3 are 15.0%, 15.0%, 93.4%, 92.7%, and 89.8%, respectively.
The modified fibroin of (2-i) may consist of the amino acid sequence set forth in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
The modified fibroin of (2-ii) may consist of an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. The modified fibroin of (2-ii) is also a protein containing the domain sequence represented by Formula 1: [(A)n motif-REP]m. The sequence identity is preferably 95% or more.
The modified fibroin of (2-ii) preferably has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, and z/w is preferably 50.9% or more, in which the total number of amino acid residues in the amino acid sequence consisting of XGX (where X represents the amino acid residue other than glycine) in the REP is z, and the total number of amino acid residues in the REP in the domain sequence is w.
The second modified fibroin may have a tag sequence at either or both of the N-terminus and the C-terminus. Therefore, it is possible to isolate, immobilize, detect, or visualize the modified fibroin.
An example of the tag sequence can include an affinity tag using specific affinity (binding property and affinity) with another molecule. A specific example of the affinity tag can include a histidine tag (His tag). The His tag is a short peptide in which about 4 to 10 histidine residues are arranged and has a property of specifically binding to a metal ion such as nickel. Thus, the His tag can be used for isolation of modified fibroin by chelating metal chromatography. A specific example of the tag sequence can include an amino acid sequence set forth in SEQ ID NO: 11 (amino acid sequence having a His tag sequence and a hinge sequence).
In addition, a tag sequence such as glutathione-S-transferase (GST) that specifically binds to glutathione or a maltose binding protein (MBP) that specifically binds to maltose can also be used.
Further, an “epitope tag” using an antigen-antibody reaction can also be used. By adding a peptide (epitope) showing antigenicity as a tag sequence, an antibody can be bound to the epitope. Examples of the epitope tag can include an HA (peptide sequence of hemagglutinin of influenza virus) tag, a myc tag, and a FLAG tag. The modified fibroin can be easily purified with high specificity by using the epitope tag.
Further, a tag sequence which can be cleaved with a specific protease can be used. By treating a protein adsorbed through the tag sequence with protease, it is also possible to recover the modified fibroin from which the tag sequence is cleaved.
A more specific example of the modified fibroin having a tag sequence can include modified fibroin having (2-iii) an amino acid sequence set forth in SEQ ID NO: 12 (PRT380), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525), or SEQ ID NO: 15 (PRT799), or (2-iv) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
Each of amino acid sequences set forth in SEQ ID NO: 16 (PRT313), SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15 is obtained by adding the amino acid sequence set forth in SEQ ID NO: 11 (having a His tag sequence and a hinge sequence) to the N-terminus of each of the amino acid sequences set forth in SEQ ID NO: 10, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
The modified fibroin of (2-iii) may consist of the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
The modified fibroin of (2-iv) may consist of an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. The modified fibroin of (2-iv) is also a protein containing the domain sequence represented by Formula 1: [(A)n motif-REP]m. The sequence identity is preferably 95% or more.
The modified fibroin of (2-iv) preferably has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, and z/w is preferably 50.9% or more, in which the total number of amino acid residues in the amino acid sequence consisting of XGX (where X represents the amino acid residue other than glycine) in the REP is z, and the total number of amino acid residues in the REP in the domain sequence is w.
The second modified fibroin may include a secretory signal for releasing the protein produced in a recombinant protein production system to the outside of a host. A sequence of the secretory signal can be appropriately set depending on a type of the host.
The domain sequence of the third modified fibroin has an amino acid sequence in which a content of an (A)n motif is reduced, as compared with the naturally derived fibroin. It can be said that the domain sequence of the third modified fibroin has an amino acid sequence corresponding to an amino acid sequence in which at least one or a plurality of (A)n motifs are deleted, as compared with the naturally derived fibroin.
The third modified fibroin may have an amino acid sequence corresponding to an amino acid sequence in which 10 to 40% of the (A)n motifs are deleted from the naturally derived fibroin.
The third modified fibroin may have an amino acid sequence corresponding to an amino acid sequence obtained by deleting one (A)n motif of every one to three (A)n motifs at least from the N-terminus to the C-terminus, as compared with the naturally derived fibroin.
The third modified fibroin may have an amino acid sequence corresponding to an amino acid sequence obtained by repeating deletion of at least two consecutive (A)n motifs and deletion of one (A)n motif in this order from the N-terminus to the C-terminus, as compared with the naturally derived fibroin.
The domain sequence of the third modified fibroin may have an amino acid sequence corresponding to an amino acid sequence obtained by deleting every other two (A)n motifs at least from the N-terminus to the C-terminus.
The third modified fibroin may contain a domain sequence represented by Formula 1: [(A)n motif-REP]m, and may have an amino acid sequence in which x/y may be 20% or more, 30% or more, 40% or more, or 50% or more, in which when the number of amino acid residues in REP's in two [(A)n motif-REP] units adjacent to each other are sequentially compared from the N-terminus to the C-terminus, and then the number of amino acid residues in REP having a small number of amino acid residues is set as 1, a maximum value of the total value obtained by summing up the number of amino acid residues in the two adjacent [(A)n motif-REP] units where the ratio of the number of amino acid residues in the other REP is 1.8 to 11.3 is x, and the total number of amino acid residues in the domain sequence is y. The number of alanine residues with respect to the total number of amino acid residues in the (A)n motif is 83% or more, preferably 86% or more, more preferably 90% or more, still more preferably 95% or more, and still more preferably 100% (which means that the (A)n motif consists of only alanine residues).
The calculation method of x/y will be described in more detail with reference to
The two adjacent [(A)n motif-REP] units are sequentially selected from the N-terminus to the C-terminus so as not to overlap. In this case, an unselected [(A)n motif-REP] unit may exist.
Next, for each pattern, the number of amino acid residues in each REP in the selected two adjacent [(A)n motif-REP] units is compared. The comparison is performed by determining a ratio of the number of amino acid residues in the other REP when one REP having a smaller number of amino acid residues is 1. For example, in the case of comparing the first REP (50 amino acid residues) with the second REP (100 amino acid residues), a ratio of the number of amino acid residues in the second REP when the first REP having a smaller number of amino acid residues is 1 is 100/50=2. Similarly, in the case of comparing the fourth REP (20 amino acid residues) with the fifth REP (30 amino acid residues), a ratio of the number of amino acid residues in the fifth REP when the fourth REP having a smaller number of amino acid residues is 1 is 30/20=1.5.
In
In each pattern, the number of all amino acid residues in two adjacent [(A)n motif-REP] units indicated by solid lines (including not only the number of amino acid residues in REP but also the number of amino acid residues in (A)n motif) are summed up. Then, the total values thus summed up are compared and the total value in the patterns at which the total value is maximized (the maximum value of the total value) is x. In the example illustrated in
Next, x/y (%) can be calculated by dividing x by the total amino acid residue number y of the domain sequence.
In the third modified fibroin, x/y is preferably 50% or more, more preferably 60% or more, still more preferably 65% or more, still more preferably 70% or more, still more preferably 75% or more, and particularly preferably 80% or more. An upper limit of x/y is not particularly limited, but may be, for example, 100% or less. In the case where the Giza ratio is 1:1.9 to 11.3, x/y is preferably 89.6% or more. In the case where the Giza ratio is 1:1.8 to 3.4, x/y is preferably 77.1% or more. In the case where the Giza ratio is 1:1.9 to 8.4, x/y is preferably 75.9% or more. In the case where the Giza ratio is 1:1.9 to 4.1, x/y is preferably 64.2% or more.
In the case where the third modified fibroin is modified fibroin in which at least a plurality of seven (A)n motifs present in the domain sequence consist of only alanine residues, x/y is preferably 46.4% or more, more preferably 50% or more, still more preferably 55% or more, still more preferably 60% or more, still more preferably 70% or more, and particularly preferably 80% or more. The upper limit of x/y is not particularly limited, but may be 100% or less.
Here, x/y in the naturally derived fibroin will be described. First, as described above, 663 types of fibroins (415 types of fibroins derived from spiders among them) were extracted by confirming fibroins with amino acid sequence information registered in NCBI GenBank by an exemplified method. x/y was calculated by the above-described calculation method from the amino acid sequences of naturally derived fibroins consisting of a domain sequence represented by Formula 1: [(A)n motif-REP]m, among all the extracted fibroins. As a result, x/y in each of the naturally derived fibroins is less than 64.2% (highest, 64.14%).
The third modified fibroin can be obtained from, for example, a cloned gene sequence of naturally derived fibroin, by deleting one or a plurality of sequences encoding an (A)n motif so that x/y is 64.2% or more. In addition, for example, the third modified fibroin can also be obtained, from the amino acid sequence of naturally derived fibroin, by designing an amino acid sequence corresponding to deletion of one or a plurality of (A)n motifs so that x/y is 64.2% or more, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence. In any case, in addition to the modification corresponding to deletion of the (A)n motif from the amino acid sequence of the naturally derived fibroin, modification of the amino acid sequence corresponding to substitution, deletion, insertion, and/or addition of one or a plurality of amino acid residues may be performed.
A more specific example of the third modified fibroin can include a modified fibroin having (3-i) an amino acid sequence set forth in SEQ ID NO: 17 (Met-PRT399), SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), or SEQ ID NO: 9 (Met-PRT799), or (3-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
The modified fibroin of (3-i) will be described. The amino acid sequence set forth in SEQ ID NO: 17 is obtained by deleting every other two (A)n motifs from the N-terminus to the C-terminus from the amino acid sequence set forth in SEQ ID NO: 10 (Met-PRT313) corresponding to the naturally derived fibroin and further inserting one [(A)n motif-REP] before the C-terminal sequence. The amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9 is as described in the second modified fibroin.
The value of x/y in the amino acid sequence set forth in SEQ ID NO: 10 (corresponding to naturally derived fibroin) at a Giza ratio of 1:1.8 to 11.3 is 15.0%. Both the value of x/y in the amino acid sequence set forth in SEQ ID NO: 17 and the value of x/y in the amino acid sequence set forth in SEQ ID NO: 7 are 93.4%. The value of x/y in the amino acid sequence set forth in SEQ ID NO: 8 is 92.7%. The value of x/y in the amino acid sequence set forth in SEQ ID NO: 9 is 89.8%. The values of z/w in the amino acid sequences set forth in SEQ ID NO: 10, SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9 are 46.8%, 56.2%, 70.1%, 66.1%, and 70.0%, respectively.
The modified fibroin of (3-i) may consist of the amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
The modified fibroin of (3-ii) may consist of an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9. The modified fibroin of (3-ii) is also a protein containing the domain sequence represented by Formula 1: [(A)n motif-REP]m. The sequence identity is preferably 95% or more.
The modified fibroin of (3-ii) preferably has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, and x/y is preferably 64.2% or more, in which when the number of amino acid residues in REP's in two [(A)n motif-REP] units adjacent to each other are sequentially compared from the N-terminus to the C-terminus, and then the number of amino acid residues in REP having a small number of amino acid residues is set as 1, a maximum value of the total value obtained by summing up the number of amino acid residues in the two adjacent [(A)n motif-REP] units where the ratio of the number of amino acid residues in the other REP is 1.8 to 11.3 (the Giza ratio is 1:1.8 to 11.3) is x, and the total number of amino acid residues in the domain sequence is y.
The third modified fibroin may have the above-described tag sequence at either or both of the N-terminus and the C-terminus.
A more specific example of the modified fibroin having a tag sequence can include modified fibroin having (3-iii) an amino acid sequence set forth in SEQ ID NO: 18 (PRT399), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525), or SEQ ID NO: 15 (PRT799), or (3-iv) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
Each of the amino acid sequences set forth in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15 is obtained by adding the amino acid sequence set forth in SEQ ID NO: 11 (having a His tag sequence and a hinge sequence) to the N-terminus of each of the amino acid sequences set forth in SEQ ID NO: 17, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
The modified fibroin of (3-iii) may consist of the amino acid sequence set forth in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
The modified fibroin of (3-iv) may consist of an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. The modified fibroin of (3-iv) is also a protein containing the domain sequence represented by Formula 1: [(A)n motif-REP]m. The sequence identity is preferably 95% or more.
The modified fibroin of (3-iv) preferably has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 18, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15, and x/y is preferably 64.2% or more, in which when the number of amino acid residues in REP's in two [(A)n motif-REP] units adjacent to each other are sequentially compared from the N-terminus to the C-terminus, and then the number of amino acid residues in REP having a small number of amino acid residues is set as 1, a maximum value of the total value obtained by summing up the number of amino acid residues in the two adjacent [(A)n motif-REP] units where the ratio of the number of amino acid residues in the other REP is 1.8 to 11.3 is x, and the total number of amino acid residues in the domain sequence is y.
The third modified fibroin may include a secretory signal for releasing the protein produced in a recombinant protein production system to the outside of a host. A sequence of the secretory signal can be appropriately set depending on a type of the host.
The domain sequence of the fourth modified fibroin has an amino acid sequence in which a content of an (A)n motif and a content of glycine residues are reduced, as compared with the naturally derived fibroin. It can be said that the domain sequence of the fourth modified fibroin has an amino acid sequence corresponding to an amino acid sequence in which at least one or a plurality of (A)n motifs are deleted and at least one or a plurality of glycine residues in REP are substituted with another amino acid residue, as compared with the naturally derived fibroin. That is, the fourth modified fibroin is modified fibroin having the characteristics of the above-described second modified fibroin and third modified fibroin. Specific aspects and the like of the fourth modified fibroin are as described in the second modified fibroin and the third modified fibroin.
A more specific example of the fourth modified fibroin can include modified fibroin having (4-i) an amino acid sequence set forth in SEQ ID NO: 7 (Met-PRT410), SEQ ID NO: 8 (Met-PRT525), SEQ ID NO: 9 (Met-PRT799), SEQ ID NO: 13 (PRT410), SEQ ID NO: 14 (PRT525), or SEQ ID NO: 15 (PRT799), or (4-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15. Specific aspects of the modified fibroin having the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15 are as described above.
The domain sequence of the fifth modified fibroin may have an amino acid sequence including a region locally having a high hydropathy index corresponding to an amino acid sequence in which one or a plurality of amino acid residues in REP are substituted with amino acid residues having a high hydropathy index and/or one or a plurality of amino acid residues having a high hydropathy index are inserted into REP, as compared with the naturally derived fibroin.
It is preferable that the region locally having a high hydropathy index consists of two to four consecutive amino acid residues.
It is more preferable that the above-described amino acid residue having a high hydropathy index is an amino acid residue selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M), and alanine (A).
The fifth modified fibroin may be further subjected to modification of an amino acid sequence corresponding to substitution, deletion, insertion, and/or addition of one or a plurality of amino acid residues as compared with the naturally derived fibroin, in addition to modification corresponding to substitution of one or a plurality of amino acid residues in REP with amino acid residues having a high hydropathy index and/or insertion of one or a plurality of amino acid residues having a high hydropathy index into REP, as compared with the naturally derived fibroin.
The fifth modified fibroin can be obtained by, for example, substituting one or a plurality of hydrophilic amino acid residues in REP (for example, amino acid residues having a negative hydropathy index) with hydrophobic amino acid residues (for example, amino acid residues having a positive hydropathy index) from a cloned gene sequence of naturally derived fibroin, and/or inserting one or a plurality of hydrophobic amino acid residues into REP. In addition, the fifth modified fibroin can be obtained by, for example, designing an amino acid sequence corresponding to substitution of one or a plurality of hydrophilic amino acid residues in REP with hydrophobic amino acid residues from an amino acid sequence of naturally derived fibroin, and/or insertion of one or a plurality of hydrophobic amino acid residues into REP, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence. In any case, in addition to modification corresponding to substitution of one or a plurality of hydrophilic amino acid residues in REP with hydrophobic amino acid residues from amino acid sequences of naturally derived fibroin, and/or insertion of one or a plurality of hydrophobic amino acid residues into REP, modification of an amino acid sequence corresponding to substitution, deletion, insertion, and/or addition of one or a plurality of amino acid residues may be further performed.
The fifth modified fibroin may contain a domain sequence represented by Formula 1: [(A)n motif-REP]m, and may have an amino acid sequence in which p/q is 6.2% or more, in which in all REP's contained in a sequence excluding a sequence from a (A)n motif located the most C-terminal side to the C-terminus of the domain sequence from the domain sequence, a total number of amino acid residues contained in a region where an average value of hydropathy indices of four consecutive amino acid residues is 2.6 or more is p, and a total number of amino acid residues contained in the sequence excluding the sequence from the (A)n motif located the most C-terminal side to the C-terminus of the domain sequence from the domain sequence is q.
A known index (Hydropathy index: Kyte J, & Doolittle R (1982), “A simple method for displaying the hydropathic character of a protein”, J. Mol. Biol., 157, pp. 105-132) is used as the hydropathy index of the amino acid residue. Specifically, the hydropathy index (hereinafter, also referred to as “HI”) of each amino acid is as shown in Table 1.
The calculation method of p/q will be described in more detail. In the calculation, the sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence represented by Formula 1: [(A)n motif-REP]m (hereinafter, referred to as “sequence A”) is used. First, in all REP's contained in the sequence A, an average value of hydropathy indices of four consecutive amino acid residues is calculated. The average value of the hydropathy indices is determined by dividing the sum of HI of each of the amino acid residues contained in the four consecutive amino acid residues by 4 (the number of amino acid residues). The average value of the hydropathy indices is determined for all of the four consecutive amino acid residues (each of the amino acid residues is used for calculating the average value 1 to 4 times). Next, a region where the average value of the hydropathy indices of the four consecutive amino acid residues is 2.6 or more is specified. Even in a case where certain amino acid residues correspond to a plurality of “four consecutive amino acid residues having an average value of hydropathy indices of 2.6 or more”, the amino acid residue is counted as one amino acid residue in the region. Then, the total number of amino acid residues contained in the region is p. In addition, the total number of amino acid residues contained in the sequence A is q.
For example, in a case where the “four consecutive amino acid residues having an average value of the hydropathy indices of 2.6 or more” are extracted from 20 places (no overlap), in the region where the average value of the hydropathy indices of four consecutive amino acid residues is 2.6 or more, the number of the four consecutive amino acid residues (no overlap) is 20, and thus p is 20×4=80. In addition, for example, in a case where two of the “four consecutive amino acid residues having an average value of the hydropathy indices of 2.6 or more” overlap by only one amino acid residue, in the region where the average value of the hydropathy indices of four consecutive amino acid residues is 2.6 or more, the number of amino acid residues is 7 (p=2×4−1=7, “−1” is the deduction of overlap). For example, in the case of the domain sequence illustrated in
In the fifth modified fibroin, p/q is preferably 6.2% or more, more preferably 7% or more, still more preferably 10% or more, still more preferably 20% or more, and still more preferably 30% or more. An upper limit of p/q is not particularly limited, but may be, for example, 45% or less.
The fifth modified fibroin can be obtained by, for example, substituting one or a plurality of hydrophilic amino acid residues in REP (for example, amino acid residues having a negative hydropathy index) with hydrophobic amino acid residues (for example, amino acid residues having a positive hydropathy index) so that a cloned amino acid sequence of naturally derived fibroin satisfies the condition of p/q, and/or modifying the cloned amino acid sequence of naturally derived fibroin with an amino acid sequence including a region locally having a high hydropathy index by inserting one or a plurality of hydrophobic amino acid residues into REP. In addition, the fifth modified fibroin can also be obtained by, for example, designing an amino acid sequence satisfying the condition of p/q from the amino acid sequence of the naturally derived fibroin, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence. In any case, modification corresponding to substitution, deletion, insertion, and/or addition of one or a plurality of amino acid residues may also be performed, in addition to modification corresponding to substitution of one or a plurality of amino acid residues in REP with amino acid residues having a high hydropathy index, and/or insertion of one or a plurality of amino acid residues having a high hydropathy index into REP, as compared with the naturally derived fibroin.
The amino acid residue having a high hydropathy index is not particularly limited, but is preferably isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M), and alanine (A), and more preferably valine (V), leucine (L), and isoleucine (I).
A more specific example of the fifth modified fibroin can include modified fibroin having (5-i) an amino acid sequence set forth in SEQ ID NO: 19 (Met-PRT720), SEQ ID NO: 20 (Met-PRT665), or SEQ ID NO: 21 (Met-PRT666), or (5-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21.
The modified fibroin of (5-i) will be described. The amino acid sequence set forth in SEQ ID NO: 19 is obtained by inserting an amino acid sequence consisting of three amino acid residues (VLI) at two sites for each REP into the amino acid sequence set forth in SEQ ID NO: 7 (Met-PRT410), except for the domain sequence at the end on the C-terminal side, and further substituting a part of glutamine (Q) residues with serine (S) residues and deleting a part of amino acids on the C-terminal side. The amino acid sequence set forth in SEQ ID NO: 20 is obtained by inserting the amino acid sequence consisting of three amino acid residues (VLI) at one site for each REP into the amino acid sequence set forth in SEQ ID NO: 8 (Met-PRT525). The amino acid sequence set forth in SEQ ID NO: 21 is obtained by inserting the amino acid sequence consisting of three amino acid residues (VLI) at two sites for each REP into the amino acid sequence set forth in SEQ ID NO: 8.
The modified fibroin of (5-i) may consist of the amino acid sequence set forth in SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21.
The modified fibroin of (5-ii) may consist of an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21. The modified fibroin of (5-ii) is also a protein containing the domain sequence represented by Formula 1: [(A)n motif-REP]m. The sequence identity is preferably 95% or more.
The modified fibroin of (5-ii) preferably has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21, and p/q is preferably 6.2% or more, in which in all REP's contained in a sequence excluding a sequence from a (A)n motif located the most C-terminal side to the C-terminus of the domain sequence from the domain sequence, a total number of amino acid residues contained in a region where an average value of hydropathy indices of four consecutive amino acid residues is 2.6 or more is p, and a total number of amino acid residues contained in the sequence excluding the sequence from the (A)n motif located the most C-terminal side to the C-terminus of the domain sequence from the domain sequence is q.
The fifth modified fibroin may have a tag sequence at either or both of the N-terminus and the C-terminus.
A more specific example of the modified fibroin having a tag sequence can include modified fibroin having (5-iii) an amino acid sequence set forth in SEQ ID NO: 22 (PRT720), SEQ ID NO: 23 (PRT665), or SEQ ID NO: 24 (PRT666), or (5-iv) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.
Each of the amino acid sequences set forth in SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 is obtained by adding the amino acid sequence set forth in SEQ ID NO: 11 (having a His tag sequence and a hinge sequence) to the N-terminus of each of the amino acid sequences set forth in SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.
The modified fibroin of (5-iii) may consist of the amino acid sequence set forth in SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.
The modified fibroin of (5-iv) may consist of an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24. The modified fibroin of (5-iv) is also a protein containing the domain sequence represented by Formula 1: [(A)n motif-REP]m. The sequence identity is preferably 95% or more.
The modified fibroin of (5-iv) preferably has 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24, and p/q is preferably 6.2% or more, in which in all REP's contained in a sequence excluding a sequence from a (A)n motif located the most C-terminal side to the C-terminus of the domain sequence from the domain sequence, a total number of amino acid residues contained in a region where an average value of hydropathy indices of four consecutive amino acid residues is 2.6 or more is p, and a total number of amino acid residues contained in the sequence excluding the sequence from the (A)n motif located the most C-terminal side to the C-terminus of the domain sequence from the domain sequence is q.
The fifth modified fibroin may include a secretory signal for releasing the protein produced in a recombinant protein production system to the outside of a host. A sequence of the secretory signal can be appropriately set depending on a type of the host.
The sixth modified fibroin has an amino acid sequence in which a content of glutamine residues is reduced, as compared with the naturally derived fibroin.
The sixth modified fibroin preferably contains at least one motif selected from a GGX motif and a GPGXX motif in the amino acid sequence of REP.
In a case where the sixth modified fibroin contains the GPGXX motif in REP, a content rate of the GPGXX motif is generally 1% or more, may be 5% or more, and is preferably 10% or more. An upper limit of the content rate of the GPGXX motif is not particularly limited, but may be 50% or less or 30% or less.
In the present specification, the “content rate of the GPGXX motif” is a value calculated by the following method.
In fibroin (modified fibroin or naturally derived fibroin) containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif, the content rate of the GPGXX motif is calculated as s/t, in which the number obtained by tripling the total number of GPGXX motifs in the regions of all REP's contained in a sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence (that is, corresponding to the total number of G and P in the GPGXX motifs) is s, and the total number of amino acid residues in all REP's excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence and further excluding the (A)n motifs is t.
For the calculation of the content rate of the GPGXX motif, the “sequence excluding a sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence” is used to exclude the effect occurring due to the fact that the “sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence” (sequence corresponding to REP) may have a sequence having a low correlation with the sequence characteristic of fibroin, which influences the calculation result of the content rate of the GPGXX motif in a case where m is small (that is, in a case where the domain sequence is short). In a case where the “GPGXX motif” is located at the C-terminus of REP, it is regarded as the “GPGXX motif” even in a case where “XX” is, for example, “AA”.
In the sixth modified fibroin, a content rate of glutamine residues is preferably 9% or less, more preferably 7% or less, still more preferably 4% or less, and particularly preferably 0%.
In the present specification, the “content rate of the glutamine residues” is a value calculated by the following method. In fibroin (modified fibroin or naturally derived fibroin) containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif, the content rate of the glutamine residues is calculated as u/t, in which a total number of glutamine residues in regions of all REP's contained in a sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence (sequence corresponding to the “region A” in
The domain sequence of the sixth modified fibroin may have an amino acid sequence corresponding to deletion of one or a plurality of glutamine residues in REP, or substitution of one or a plurality of glutamine residues with another amino acid residue, as compared with the naturally derived fibroin.
“Another amino acid residue” may be an amino acid residue other than a glutamine residue, but is preferably an amino acid residue having a higher hydropathy index than that of a glutamine residue. The hydropathy index of the amino acid residue is shown in Table 1.
As shown in Table 1, examples of the amino acid residue having a higher hydropathy index than that of a glutamine residue can include an amino acid residue selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M) alanine (A), glycine (G), threonine (T), serine (S), tryptophan (W), tyrosine (Y), proline (P), and histidine (H). Among them, an amino acid residue selected from isoleucine (I), valine (V), leucine (L), phenylalanine (F), cysteine (C), methionine (M), and alanine (A) is more preferred, and an amino acid residue selected from isoleucine (I), valine (V), leucine (L), and phenylalanine (F) is still more preferred.
In the sixth modified fibroin, hydrophobicity of REP is preferably −0.8 or more, more preferably −0.7 or more, still more preferably 0 or more, still more preferably 0.3 or more, and still more preferably 0.4 or more. An upper limit of the hydrophobicity of REP is not particularly limited, but may be 1.0 or less or 0.7 or less.
In the present specification, the “hydrophobicity of REP” is a value calculated by the following method.
In fibroin (modified fibroin or naturally derived fibroin) containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif, the hydrophobicity of REP is calculated as v/t, in which the sum of hydropathy indices of the amino acid residues in the regions of all REP's contained in the sequence excluding the sequence from the (A)n motif located at the most C-terminal side to the C-terminus of the domain sequence from the domain sequence (sequence corresponding to the “region A” in
The sixth modified fibroin may be further subjected to modification of an amino acid sequence corresponding to substitution, deletion, insertion, and/or addition of one or a plurality of amino acid residues, in addition to modification corresponding to deletion of one or a plurality of glutamine residues in REP, and/or substitution of one or a plurality of glutamine residues in REP with another amino acid residue, as compared to naturally derived fibroin.
The sixth modified fibroin can be obtained by, for example, deleting one or a plurality of glutamine residues in REP from a cloned gene sequence of naturally derived fibroin, and/or substituting one or a plurality of glutamine residues in REP with another amino acid residue. In addition, the sixth modified fibroin can be obtained by, for example, designing an amino acid sequence corresponding to deletion of one or a plurality of glutamine residues in REP from an amino acid sequence of naturally derived fibroin, and/or substitution of one or a plurality of glutamine residues in REP with another amino acid residue, and chemically synthesizing a nucleic acid encoding the designed amino acid sequence.
More specific examples of the sixth modified fibroin can include modified fibroin having (6-i) an amino acid sequence set forth in SEQ ID NO: 25 (Met-PRT888), SEQ ID NO: 26 (Met-PRT965), SEQ ID NO: 27 (Met-PRT889), SEQ ID NO: 28 (Met-PRT916), SEQ ID NO: 29 (Met-PRT918), SEQ ID NO: 30 (Met-PRT699), SEQ ID NO: 31 (Met-PRT698), SEQ ID NO: 32 (Met-PRT966), SEQ ID NO: 41 (Met-PRT917), or SEQ ID NO: 42 (Met-PRT1028), and modified fibroin having (6-ii) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41, or SEQ ID NO: 42.
The modified fibroin of (6-i) will be described. The amino acid sequence set forth in SEQ ID NO: 25 is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 7 (Met-PRT410) with VL. The amino acid sequence set forth in SEQ ID NO: 26 is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 7 with TS and substituting the remaining Q with A. The amino acid sequence set forth in SEQ ID NO: 27 is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 7 with VL and substituting the remaining Q with I. The amino acid sequence set forth in SEQ ID NO: 28 is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 7 with VI and substituting the remaining Q with L. The amino acid sequence set forth in SEQ ID NO: 29 is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 7 with VF and substituting the remaining Q with I.
The amino acid sequence set forth in SEQ ID NO: 30 is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 8 (Met-PRT525) with VL. The amino acid sequence set forth in SEQ ID NO: 31 is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 8 with VL and substituting the remaining Q with I.
The amino acid sequence set forth in SEQ ID NO: 32 is obtained by substituting, with VF, all QQs in a sequence obtained by repeating a region of 20 domain sequences present in the amino acid sequence set forth in SEQ ID NO: 7 (Met-PRT410) two times and substituting the remaining Q with I.
The amino acid sequence set forth in SEQ ID NO: 41 (Met-PRT917) is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 7 with LI and substituting the remaining Q with V. The amino acid sequence set forth in SEQ ID NO: 42 (Met-PRT1028) is obtained by substituting all QQs in the amino acid sequence set forth in SEQ ID NO: 7 with IF and substituting the remaining Q with T.
The content rate of the glutamine residues in each of the amino acid sequences set forth in SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41, and SEQ ID NO: 42 is 9% or less (Table 2).
The modified fibroin of (6-i) may consist of the amino acid sequence set forth in SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41, or SEQ ID NO: 42.
The modified fibroin of (6-ii) may consist of the amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41, or SEQ ID NO: 42. The modified fibroin of (6-ii) is also a protein containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif. The sequence identity is preferably 95% or more.
It is preferable that a content rate of glutamine residues in the modified fibroin of (6-ii) is preferably 9% or less. In addition, it is preferable that a content rate of a GPGXX motif in the modified fibroin of (6-ii) is preferably 10% or more.
The sixth modified fibroin may have a tag sequence at either or both of the N-terminus and the C-terminus. Therefore, it is possible to isolate, immobilize, detect, or visualize the modified fibroin.
More specific examples of the modified fibroin having a tag sequence can include modified fibroin having (6-iii) an amino acid sequence set forth in SEQ ID NO: 33 (PRT888), SEQ ID NO: 34 (PRT965), SEQ ID NO: 35 (PRT889), SEQ ID NO: 36 (PRT916), SEQ ID NO: 37 (PRT918), SEQ ID NO: 38 (PRT699), SEQ ID NO: 39 (PRT698), SEQ ID NO: 40 (PRT966), SEQ ID NO: 43 (PRT917), or SEQ ID NO: 44 (PRT1028), or modified fibroin having (6-iv) an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, or SEQ ID NO: 44.
Each of the amino acid sequences set forth in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, and SEQ ID NO: 44 is obtained by adding the amino acid sequence set forth in SEQ ID NO: 11 (having a His tag sequence and a hinge sequence) to the N-terminus of each of the amino acid sequences set forth in SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 41, and SEQ ID NO: 42. Since only the tag sequence is added to the N-terminus, the content rate of the glutamine residues is not changed, and the content rate of the glutamine residues in each of the amino acid sequences set forth in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, or SEQ ID NO: 44 is 9% or less (Table 3).
The modified fibroin of (6-iii) may consist of the amino acid sequence set forth in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, or SEQ ID NO: 44.
The modified fibroin of (6-iv) may consist of the amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 43, or SEQ ID NO: 44. The modified fibroin of (6-iv) is also a protein containing a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m−(A)n motif. The sequence identity is preferably 95% or more.
It is preferable that a content rate of glutamine residues in the modified fibroin of (6-iv) is preferably 9% or less. In addition, it is preferable that a content rate of a GPGXX motif in the modified fibroin of (6-iv) is preferably 10% or more.
The sixth modified fibroin may include a secretory signal for releasing the protein produced in a recombinant protein production system to the outside of a host. A sequence of the secretory signal can be appropriately set depending on a type of the host.
The modified fibroin may be modified fibroin having at least two or more characteristics of the characteristics of the first modified fibroin, the second modified fibroin, the third modified fibroin, the fourth modified fibroin, the fifth modified fibroin, and the sixth modified fibroin.
The modified fibroin may be hydrophilic modified fibroin or hydrophobic modified fibroin. The hydrophobic modified fibroin is modified fibroin in which a value obtained by determining the sum of hydropathy indices (HI) of all amino acid residues constituting the modified fibroin and then dividing the sum by the number of all amino acid residues (average HI) is 0 or more. The hydropathy index is as shown in Table 1. In addition, the hydrophilic modified fibroin is modified fibroin in which the average HI is less than 0. From the viewpoint of obtaining more excellent shrinkage resistance to water, the average hydropathy index (HI) of the modified fibroin according to the present embodiment is preferably −1.3 or more, preferably −0.8 or more, preferably more than −0.8, preferably −0.7 or more, preferably −0.6 or more, more preferably −0.5 or more, more preferably −0.4 or more, more preferably −0.3 or more, more preferably −0.2 or more, more preferably −0.1 or more, more preferably 0 or more, more preferably 0.1 or more, more preferably 0.2 or more, still more preferably 0.3 or more, and particularly preferably 0.4 or more. In addition, the average hydropathy index (HI) may be 1.5 or less, 1.4 or less, or 1.3 or less.
An example of the hydrophobic modified fibroin can include the above-described sixth modified fibroin. A more specific example of the hydrophobic modified fibroin can include modified fibroin having an amino acid sequence set forth in SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 43, or an amino acid sequence set forth in SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, or SEQ ID NO: 44.
Examples of the hydrophilic modified fibroin can include the above-described first modified fibroin, second modified fibroin, third modified fibroin, fourth modified fibroin, and fifth modified fibroin. A more specific example of the hydrophilic modified fibroin can include fibroin having an amino acid sequence set forth in SEQ ID NO: 4, an amino acid sequence set forth in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, an amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 11, SEQ ID NO: 14, or SEQ ID NO: 15, an amino acid sequence set forth in SEQ ID NO: 18, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, an amino acid sequence set forth in SEQ ID NO: 17, SEQ ID NO: 11, SEQ ID NO: 14, or SEQ ID NO: 15, or an amino acid sequence set forth in SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21.
(Production Method of Modified Fibroin)
All of the modified fibroins according to the embodiment can be produced by, for example, expressing a nucleic acid by a nucleic acid sequence encoding the modified fibroin and a host transformed with an expression vector having one or a plurality of regulatory sequences operably linked to the nucleic acid sequence.
A production method of a nucleic acid encoding the modified fibroin is not particularly limited. For example, the nucleic acid can be produced by a method in which a gene encoding natural fibroin is amplified and cloned by a polymerase chain reaction (PCR) or the like, and the amplified and cloned gene is modified by a genetic engineering method, or a method of chemically synthesizing a nucleic acid. A method of chemically synthesizing a nucleic acid is not particularly limited. For example, genes can be chemically synthesized by a method of linking, by PCR or the like, oligonucleotides that are automatically synthesized by AKTA oligopilot plus 10/100 (GE Healthcare Japan Ltd.) or the like, based on the amino acid sequence information of fibroin obtained from the web database of NCBI and the like. In this case, in order to facilitate purification and/or confirmation of the modified fibroin, a nucleic acid encoding modified fibroin consisting of an amino acid sequence obtained by adding an amino acid sequence consisting of a start codon and a His10 tag to the N-terminus of the above amino acid sequence may be synthesized.
The regulatory sequence is a sequence that controls the expression of modified fibroin in a host (for example, a promoter, an enhancer, a ribosome binding sequence, a transcription termination sequence, or the like), and can be appropriately selected depending on the type of the host. As a promoter, an inducible promoter which functions in host cells and is capable of inducing expression of modified fibroin may be used. An inducible promoter is a promoter that can control transcription due to the presence of an inducer (expression inducer), the absence of a repressor molecule, or a physical factor such as an increase or decrease in temperature, osmotic pressure, or pH value.
The type of the expression vector such as a plasmid vector, a viral vector, a cosmid vector, a fosmid vector, or an artificial chromosome vector can be appropriately selected depending on the type of the host. As the expression vector, an expression vector which can automatically replicate in a host cell or can be incorporated into a chromosome of a host and which contains a promoter at a position capable of transcribing the nucleic acid encoding the modified fibroin is suitably used.
Both a prokaryote and a eukaryote such as yeast, filamentous fungi, insect cells, animal cells, and plant cells can be suitably used as hosts.
Preferred examples of the host of the prokaryote can include bacteria belonging to the genus Escherichia, the genus Brevibacillus, the genus Serratia, the genus Bacillus, the genus Microbacterium, the genus Brevibacterium, the genus Corynebacterium, and the genus Pseudomonas. An example of microorganisms belonging to the genus Escherichia can include E. coli. An example of microorganisms belonging to the genus Brevibacillus can include Brevibacillus agri. An example of microorganisms belonging to the genus Serratia can include Serratia liquefaciens. An example of microorganisms belonging to the genus Bacillus can include Bacillus subtilis. An example of microorganisms belonging to the genus Microbacterium can include Microbacterium ammoniaphilum. An example of microorganisms belonging to the genus Brevibacterium can include Brevibacterium divaricatum. An example of microorganisms belonging to the genus Corynebacterium can include Corynebacterium ammoniagenes. An example of microorganisms belonging to the genus Pseudomonas can include Pseudomonas putida.
In a case where a prokaryote is used as a host, examples of a vector into which a nucleic acid encoding the modified fibroin is introduced can include pBTrp2 (manufactured by Boehringer Mannheim GmbH), pGEX (manufactured by Pharmacia Corporation), and pUC18, pBluescriptII, pSupex, pET22b, pCold, pUB110, and pNCO2 (JP 2002-238569 A).
Examples of the eukaryotic host can include yeast and filamentous fungi (mold or the like). An example of the yeast can include yeast which belongs to the genus Saccharomyces, the genus Pichia, or the genus Schizosaccharomyces. An example of filamentous fungi can include filamentous fungi belonging to the genus Aspergillus, the genus Penicillium, or the genus Trichoderma.
In a case where a eukaryote is used as a host, examples of a vector into which a nucleic acid encoding the modified fibroin is introduced can include YEP13 (ATCC37115) and YEp24 (ATCC37051). As a method of introducing an expression vector into the host cell, any method can be used as long as a DNA is introduced into the host cell. Examples thereof can include a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], an electroporation method, a spheroplast method, a protoplast method, a lithium acetate method, and a competent method.
As a method of expressing a nucleic acid by a host transformed with an expression vector, secretory production, fusion protein expression, or the like, can be performed according to the method described in Molecular Cloning, 2nd edition, in addition to direct expression.
The modified fibroin can be produced by, for example, culturing a host transformed with the expression vector in a culture medium, producing and accumulating the modified fibroin in the culture medium, and then collecting the modified fibroin from the culture medium. A method of culturing the host in the culture medium can be performed according to a method commonly used for culturing a host.
In the case where the host is a prokaryote such as E. coli or a eukaryote such as yeast, any of a natural medium and a synthetic medium may be used as a culture medium as long as it contains a carbon source, a nitrogen source, inorganic salts, and the like which can be assimilated by the host and it is a medium capable of efficiently culturing the host.
As the carbon source, any carbon source that can be assimilated by the transformed microorganisms may be used, and it is possible to use, for example, carbohydrate such as glucose, fructose, sucrose, or molasses, starch, or starch hydrolyzates containing the carbohydrate, organic acid such as acetic acid or propionic acid, and alcohol such as ethanol or propanol. As the nitrogen source, for example, it is possible to use an ammonium salt of inorganic or organic acid such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, or ammonium phosphate, other nitrogen-containing compounds, peptone, meat extract, yeast extract, corn steep liquor, casein hydrolyzate, soybean cake, soybean cake hydrolyzate, and various fermentative bacteria and digested products thereof. As the inorganic salts, for example, it is possible to use monopotassium phosphate, dipotassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, and calcium carbonate.
A prokaryote such as E. coli or a eukaryote such as yeast can be cultured under aerobic conditions such as shaking culture or deep aeration stirring culture. A culture temperature is, for example, 15 to 40° C. A culture time is generally 16 hours to 7 days. It is preferable to maintain a pH of the culture medium during the culture at 3.0 to 9.0. The pH of the culture medium can be adjusted using inorganic acid, organic acid, an alkali solution, urea, calcium carbonate, ammonia, or the like.
In addition, antibiotics such as ampicillin and tetracycline may be added to the culture medium during the culture, if necessary. When culturing microorganisms transformed with an expression vector using an inducible promoter as a promoter, an inducer may be added to the medium, if necessary. For example, when culturing microorganisms transformed with an expression vector using a lac promoter, isopropyl-3-D-thiogalactopyranoside or the like may be added to the medium, and when culturing microorganisms transformed with an expression vector using a trp promoter, indole acrylic acid or the like may be added to the medium.
Isolation and purification of the expressed modified fibroin can be performed by a commonly used method. For example, in the case where the modified fibroin is expressed in a dissolved state in cells, the host cells are collected by centrifugation after completion of the culture, the collected cells are suspended in an aqueous buffer, and then the host cells are disrupted using an ultrasonicator, a French press, a Manton-Gaulin homogenizer, a Dyno-Mill, or the like to obtain a cell-free extract. From the supernatant obtained by centrifuging the cell-free extract, a purified preparation can be obtained by a method commonly used for isolation and purification of a protein, that is, a solvent extraction method, a salting-out method using ammonium sulfate or the like, a desalting method, a precipitation method using an organic solvent, an anion exchange chromatography method using a resin such as diethylaminoethyl (DEAE)-Sepharose or DIAION HPA-75 (manufactured by Mitsubishi Kasei Kogyo Kabushiki Kaisha), a cation exchange chromatography method using a resin such as S-Sepharose FF (Pharmacia Corporation), a hydrophobic chromatography method using a resin such as butyl sepharose or phenyl sepharose, a gel filtration method using a molecular sieve, an affinity chromatography method, a chromatofocusing method, an electrophoresis method such as isoelectric focusing or the like, alone or in combination thereof.
In addition, in the case where the modified fibroin is expressed by formation of an insoluble matter in cells, similarly, the host cells are collected, disrupted, and then centrifuged to recover the insoluble matter of the modified fibroin as a precipitated fraction. The recovered insoluble matter of the modified fibroin can be solubilized with a protein denaturing agent. After this operation, a purified preparation of the modified fibroin can be obtained by the same isolation and purification method as described above. In the case where the modified fibroin is secreted extracellularly, the modified fibroin can be recovered from the culture supernatant. That is, a culture supernatant can be obtained by treating the culture by a method such as centrifugation, and a purified preparation can be obtained from the culture supernatant using the same isolation and purification method as described above.
[Spinning Raw Material Solution]
A spinning raw material solution (dope solution) according to the present embodiment contains modified fibroin and a solvent.
Any solvent can be used in the spinning raw material solution according to the present embodiment as long as it can dissolve the modified fibroin, and examples thereof can include hexafluoroisopropanol (HFIP), hexafluoroacetone (HFA), dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), 1,3-dimethyl-2-imidazolidone (DMI), N-methyl-2-pyrrolidone (NMP), acetonitrile, N-methylmorpholine N-oxide (NMO), and formic acid. Hexafluoroisopropanol, dimethyl sulfoxide, or formic acid is more preferred, and dimethyl sulfoxide or formic acid is still more preferred, from the viewpoint of more preferred solubility of the modified fibroin. Theses organic solvent may also contain water. These solvents may be used alone or as a mixture of two or more thereof.
A concentration of the modified fibroin in the spinning raw material solution according to the present embodiment is preferably 5 to 40 wt %, more preferably 7 to 40 wt %, still more preferably 10 to 40 wt %, still more preferably 7 to 35 wt %, still more preferably 10 to 35 wt %, still more preferably 12 to 35 wt %, still more preferably 15 to 35 wt %, still more preferably 15 to 30 wt %, still more preferably 20 to 35 wt %, particularly preferably 20 to 30 wt %, and particularly preferably 25 to 35 wt %, with respect to 100 wt % of a total amount of the spinning raw material solution. When the concentration of the modified fibroin is 5 wt % or more, productivity is further improved. When the concentration of the modified fibroin is 40 wt % or less, the spinning raw material solution can be more stably discharged from a spinneret, resulting in an improvement of productivity.
An inorganic salt may be added to the spinning raw material solution according to the present embodiment, if necessary. The inorganic salt can function as a dissolution accelerator for the modified fibroin. Examples of the inorganic salt can include an alkaline metal halide, an alkaline earth metal halide, and an alkaline earth metal nitrate. Specific examples of the inorganic salt can include lithium carbonate, lithium chloride, calcium chloride, calcium nitrate, lithium bromide, barium bromide, calcium bromide, barium chlorate, sodium perchlorate, lithium perchlorate, barium perchlorate, calcium perchlorate, and magnesium perchlorate. At least one of these inorganic salts may be added to the solvent.
A preparation method of the spinning raw material solution according to the present embodiment is not particularly limited, but the modified fibroin and the solvent may be mixed with each other in any order. The spinning raw material solution may be stirred or shaken for a predetermined time in order to accelerate dissolution. In this case, the spinning raw material solution may be heated to a temperature at which the spinning raw material solution can be dissolved depending on the used modified fibroin and solvent, if necessary. The spinning raw material solution may be heated to, for example, 30° C. or higher, 40° C. or higher, 50° C. or higher, 60° C. or higher, 70° C. or higher, 80° C. or higher, or 90° C. or higher. An upper limit of the heating temperature is, for example, equal to or lower than a boiling point of the solvent.
A viscosity of the spinning raw material solution according to the present embodiment may be appropriately set according to use or a spinning method of a fiber. For example, the viscosity of the spinning raw material solution at 40° C. may be 1,000 to 35,000 mPa·sec, 1,000 to 30,000 mPa·sec, 1,000 to 20,000 mPa·sec, 3,000 to 20,000 mPa·sec, 5,000 to 30,000 mPa·sec, 5,000 to 15,000 mPa·sec, 5,000 to 12,000 mPa·sec, 5,000 to 10,000 mPa·sec, 7,000 to 30,000 mPa·sec, 7,000 to 12,000 mPa·sec, or 10,000 to 30,000 mPa·sec. The viscosity of the spinning raw material solution can be measured using an “EMS viscometer” (trade name) manufactured by Kyoto Electronics Manufacturing Co., Ltd.
[Raw Material Fiber]
A raw material fiber according to the present embodiment is obtained by spinning the modified fibroin described above, and contains the modified fibroin described above as a main component. The raw material fiber according to the present embodiment is a fiber obtained after the spinning and before being irreversibly shrunk. A fiber diameter of the raw material fiber preferably exceeds 25 μm.
A lower limit of the fiber diameter of the raw material fiber preferably exceeds 25 μm, and may be 28 μm or more, 30 μm or more, 32 μm or more, 34 μm or more, 35 μm or more, 36 μm or more, 38 μm or more, 40 μm or more, 45 μm or more, 50 μm or more, 55 μm or more, or 65 μm or more.
An upper limit of the fiber diameter of the raw material fiber is preferably 120 μm or less, and may be 115 μm or less, 110 μm or less, 105 μm or less, 100 μm or less, 95 μm or less, 90 μm or less, 85 μm or less, 80 μm or less, or 75 μm or less.
The fiber diameter of the raw material fiber may be more than 25 μm to 120 μm, more than 25 μm to 115 μm, more than 25 μm to 110 μm, more than 25 μm to 105 μm, more than 25 μm to 100 μm, more than 25 μm to 95 μm, more than 25 μm to 90 μm, more than 25 μm to 85 μm, 30 μm to 120 μm, 30 μm to 115 μm, 30 μm to 110 μm, 30 μm to 105 μm, 30 μm to 100 μm, 30 μm to 95 μm, 30 μm to 90 μm, 30 μm to 85 μm, 35 μm to 120 μm, 35 μm to 115 μm, 35 μm to 110 μm, 35 μm to 105 μm, 35 μm to 100 μm, 35 μm to 95 μm, 35 μm to 90 μm, 35 μm to 85 μm, 40 μm to 120 μm, 40 μm to 115 μm, 40 μm to 110 μm, 40 μm to 105 μm, 40 μm to 100 μm, 40 μm to 95 μm, 40 μm to 90 μm, 40 μm to 85 μm, 45 μm to 120 μm, 45 μm to 115 μm, 45 μm to 110 μm, 45 μm to 105 μm, 45 μm to 100 μm, 45 μm to 95 μm, 45 μm to 90 μm, 45 μm to 85 μm, 48 μm to 120 μm, 48 μm to 115 μm, 48 μm to 110 μm, 48 μm to 105 μm, 48 μm to 100 μm, 48 μm to 95 μm, 48 μm to 90 μm, 48 μm to 85 μm, 50 μm to 120 μm, 50 μm to 115 μm, 50 μm to 110 μm, 50 μm to 105 μm, 50 μm to 100 μm, 50 μm to 95 μm, 50 μm to 90 μm, 50 μm to 85 μm, 55 μm to 120 μm, 55 μm to 115 μm, 55 μm to 110 μm, 55 μm to 105 μm, 55 μm to 100 μm, 55 μm to 95 μm, 55 μm to 90 μm, 55 μm to 85 μm, 55 μm to 80 μm, 60 μm to 120 μm, 60 μm to 115 μm, 60 μm to 110 μm, 60 μm to 105 μm, 60 μm to 100 μm, 60 μm to 95 μm, 60 μm to 90 μm, 60 μm to 85 μm, 55 μm to 120 μm, 55 μm to 115 μm, 55 μm to 110 μm, 55p to 105 μm, 55 μm to 100 μm, 55 μm to 95 μm, 55 μm to 90 μm, 55 μm to 85 μm, 65 μm to 120 μm, 65 μm to 115 μm, 65 μm to 110 μm, 65 μm to 105 μm, 65 μm to 100 μm, 65 μm to 95 μm, 65 μm to 90 μm, 65 μm to 85 μm, or 60 μm to 80 μm. When the fiber diameter exceeds 25 μm, it is possible to reduce the shrinkage due to contact with water. When the fiber diameter is 120 μm or less, desolvation when forming the fiber can be further efficiently performed.
Production Method of Raw Material Fiber
Spinning Step
A production method of the raw material fiber according to the present embodiment can be performed by a known wet spinning method, a dry spinning method, a dry wet spinning method, a melt spinning method, or the like. The production method of the raw material fiber of the present embodiment can be performed by, for example, using a spinning apparatus illustrated in
The extrusion device 1 has a storage tank 7, and a spinning raw material solution (dope solution) 6 is stored herein. A coagulation liquid 11 is stored in the coagulation bath 20. The spinning raw material solution 6 is extruded from a spinneret (nozzle) 9 by a gear pump 8 attached to a lower end portion of the storage tank 7. In a laboratory scale, the spinning raw material solution may be added in a cylinder and extruded from the nozzle using a syringe pump or the like. The extruded spinning raw material solution 6 is fed (introduced) to the coagulation liquid 11 in the coagulation bath 20 via an air gap 19. In the coagulation liquid 11, the solvent is removed from the spinning raw material solution to coagulate the modified fibroin to form a fibrous coagulant. Next, the fibrous coagulant is fed into a washing solution 12 in the washing bath 21 to be drawn. A draw ratio is determined according to a speed ratio of a first nip roller 13 and a second nip roller 14 that are installed in the washing bath 21. Thereafter, the drawn fibrous coagulant is fed into the drying device 4 to be dried in a yarn path 22, and then the dried fibrous coagulant is wound around a winder. By doing so, the raw material fiber is finally obtained as a wound product 5 wound around the winder by the spinning apparatus 10. Reference numerals 18a to 18g represent yarn guides.
The coagulation liquid 11 may be any solvent that can be desolvated, and examples thereof can include a lower alcohol having 1 to 5 carbon atoms such as methanol, ethanol, or 2-propanol, and acetone. Water may be appropriately contained in the coagulation liquid 11. In a case where a syringe pump having a nozzle with a diameter of 0.1 to 0.6 mm is used as the spinneret 9, an extrusion speed is preferably 0.2 to 6.0 ml/hr and more preferably 1.4 to 4.0 ml/hr per hole. A distance in which the coagulated modified fibroin passes through the coagulation liquid 11 (substantially, a distance from the yarn guide 18a to the yarn guide 18b) may be any length that enables efficient desolvation, and is, for example, 200 to 500 mm. A withdrawing speed of an undrawn yarn may be, for example, 1 to 100 m/min, or 1 to 20 m/min, and is preferably 1 to 3 m/min. When the withdrawing speed is 1 m/min or higher, productivity can be sufficiently increased. When the withdrawing speed is 100 m/min or lower, it is possible to remarkably prevent liquid scattering of the solvent. A retention time in the coagulation liquid 11 may be any time as long as the solvent is removed from the spinning raw material solution, and the retention time may be, for example, 0.01 to 3 minutes, and is preferably 0.05 to 0.15 minutes. In addition, the drawing (pre-drawing) may be performed in the coagulation liquid 11. The coagulation bath 20 may be provided in multiple stages, and the drawing may be performed in each stage or in a specific stage, if necessary.
A spinneret shape, a hole shape, the number of holes, or the like of the spinneret is not particularly limited, but can be appropriately selected depending on a desired fiber diameter and the number of single yarns.
In a case where the hole shape of the spinneret is a circular shape, a hole diameter thereof can be 0.01 mm to 0.6 mm. When the hole diameter is 0.01 mm or more, a pressure loss can be reduced and an equipment cost can thus be saved. When the hole diameter is 0.6 mm or less, it is possible to reduce the necessity of a drawing operation for reducing the fiber diameter, and it is possible to reduce possibility of drawing breakage during the operation from discharging to withdrawing.
A temperature of the spinning raw material solution when passing through the spinneret and a temperature of the spinneret are not particularly limited, but may be appropriately adjusted depending on a concentration and viscosity of the spinning raw material solution to be used, a type of the organic solvent, and the like. The temperature is preferably 30° C. to 100° C., from the viewpoint of preventing a deterioration of the modified fibroin. In addition, an upper limit of the temperature is preferably a temperature lower than a boiling point of the solvent to be used, from the viewpoint of reducing an increase in pressure due to volatilization of the solvent and the possibility of blockage in a pipe due to solidification of the spinning raw material solution. By doing so, process stability is improved.
A temperature of the coagulation liquid 11 is not particularly limited, but may be 40° C. or lower, 30° C. or lower, 25° C. or lower, 20° C. or lower, 10° C. or lower, or 5° C. or lower. The temperature of the coagulation liquid 11 is preferably 0° C. or higher, from the viewpoint of workability, a cooling cost, or the like. The temperature of the coagulation liquid 11 can be adjusted by, for example, using the spinning apparatus 10 including the coagulation bath 20 in which a heat exchanger is provided and a cooling and circulation device. For example, by flowing a medium cooled to a predetermined temperature in the cooling and circulation device to the heat exchanger installed in the coagulation bath 20, the temperature can be adjusted within the above range by heat exchange between the coagulation liquid 11 and the heat exchanger. In this case, the cooling is more efficiently performed by circulating the solvent used in the coagulation liquid 11 as the medium.
A plurality of coagulation baths in which the coagulation liquid is stored may be provided.
The coagulated modified fibroin (fibrous coagulant) may be wound around the winder as it is after released from the coagulation bath or the washing bath, or may be wound around the winder after passing through the drying device to be dried.
A distance in which the coagulated modified fibroin (fibrous coagulant) passes through the coagulation liquid may be determined depending on an extrusion speed (discharge speed) of the spinning raw material solution from the nozzle, as long as desolvation is efficiently performed. A retention time of the coagulated modified fibroin (or the spinning raw material solution) in the coagulation liquid may be determined depending on the distance in which the coagulated modified fibroin passes through the coagulation liquid, the extrusion speed of the spinning raw material solution from the nozzle, and the like.
[Drawing Step]
The production method of the raw material fiber according to the present embodiment may further include a step of drawing the coagulated modified fibroin (fibrous coagulant) (drawing step). Examples of the drawing method can include wet heat drawing and dry heat drawing. The drawing step may be performed in, for example, the coagulation bath 20 or the washing bath 21. In addition, the drawing step can be performed in the air.
The drawing performed in the washing bath 21 may be so-called wet heat drawing which is performed in warm water, a solution obtained by adding an organic solvent or the like to warm water, or the like. A temperature in the wet heat drawing is preferably 50 to 90° C. When the temperature is 50° C. or higher, it is possible to make a pore diameter of the yarn small and stable. In addition, when the temperature is 90° C. or lower, the temperature is easily set, which improves spinning stability. The temperature is more preferably 75 to 85° C.
The wet heat drawing can be performed in warm water, a solution obtained by adding an organic solvent or the like to warm water, or heated steam. The temperature may be, for example, 40 to 200° C., 50 to 180° C., 50 to 150° C., or 75 to 90° C. A draw ratio in the wet heat drawing may be, for example, 1 to 30 times, 2 to 25 times, 2 to 20 times, 2 to 15 times, 2 to 10 times, 2 to 8 times, 2 to 6 times, or 2 to 4 times, with respect to the undrawn yarn (or pre-drawn yarn). However, the draw ratio is not limited as long as it is within a range in which characteristics such as a desired fiber thickness and mechanical properties can be obtained.
The dry heat drawing can be performed in the air using a device provided with a heat source such as a contact type heat plate and a non-contact type furnace, but the present invention is not particularly limited thereto. Any device may be used as long as a fiber can be heated to a predetermined temperature and to be drawn at a predetermined ratio. The temperature may be, for example, 100° C. to 270° C., 140° C. to 230° C., 140° C. to 200° C., 160° C. to 200° C., or 160° C. to 180° C.
The draw ratio in the dry heat drawing step may be, for example, 1 to 30 times, 2 to 30 times, 2 to 20 times, 3 to 15 times, 3 to 10 times, 3 to 8 times, or 4 to 8 times, with respect to the undrawn yarn (or pre-drawn yarn). However, the draw ratio is not limited as long as it is within a range in which characteristics such as a desired fiber thickness and mechanical properties can be obtained.
In the drawing step, the wet heat drawing and the dry heat drawing may be performed independently of each other, or may be performed in multiple stages or in combination thereof. That is, in the drawing step, the wet heat drawing and the dry wet drawing can be performed in an appropriate combination in a manner that the wet heat drawing is performed as first stage drawing and the dry heat drawing is performed as second stage drawing, or the wet heat drawing is performed as first stage drawing, the wet heat drawing is performed as second stage drawing, and the dry heat drawing is performed as third stage drawing.
A lower limit of the final draw ratio of the raw material fiber subjected to the drawing step is preferably any of 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, or 9 times, with respect to the undrawn yarn (or pre-drawn yarn). An upper limit of the final draw ratio of the raw material fiber subjected to the drawing step is preferably any of 40 times, 30 times, 20 times, 15 times, 14 times, 13 times, 12 times, 11 times, or 10 times. In addition, the final draw ratio may be, for example, 3 to 40 times, 3 to 30 times, 5 to 30 times, 5 to 20 times, 5 to 15 times, or 5 to 13 times. However, the draw ratio is not limited as long as it is within a range in which characteristics such as a desired fiber thickness and mechanical properties can be obtained. By adjusting the draw ratio, the fiber diameter of the obtained raw material fiber can be adjusted to an arbitrary value.
In order to apply charging suppressing properties, convergence properties, lubricity, and the like, an oil agent may be applied to the undrawn yarn (or pre-drawn yarn) or the drawn yarn before or after the drying, if necessary. A type and the amount of the oil agent to be applied are not particularly limited, but can be appropriately adjusted in consideration of use of the fiber, handleability of the fiber, and the like.
The production method according to the present embodiment may further include a step of filtering the spinning raw material solution before discharging of the spinning raw material solution (filtration step), and/or a step of defoaming the spinning raw material solution before discharging (defoaming step).
[Production Method of Modified Fibroin Fiber (Shrinking Step)]
The modified fibroin fiber according to the present embodiment can be produced by the method including the shrinking step of irreversibly shrinking the raw material fiber described above. In the shrinking step of irreversibly shrinking the raw material fiber, the raw material fiber may be irreversibly shrunk by bringing the raw material fiber into contact with water, or the raw material fiber may be irreversibly shrunk by heating and relaxing the raw material fiber. In the case where the raw material fiber is irreversibly shrunk by bringing the raw material fiber into contact with water, the irreversibly shrunk fiber may be dried and further shrunk.
[Shrinking Step by Contact with Water (Contact Step)]
It is considered that the irreversible shrinkage of the raw material fiber (fiber containing the modified fibroin) in the contact step (“primary shrinkage” in
In the contact step, the raw material fiber before being brought into contact with water after spinning is brought into contact with water to bring the raw material fiber into a wet state. The wet state refers to a state in which at least a part of the raw material fiber is wetted with water. Therefore, the raw material fiber can be shrunk regardless of an external force. This shrinkage is irreversible (corresponding to the “primary shrinkage” in
A temperature of the water coming into contact with the raw material fiber in the contact step may be lower than a boiling point. Therefore, handleability, workability in the shrinking step, and the like are improved. In addition, a lower limit of the temperature of the water is preferably 10° C. or higher, more preferably 40° C. or higher, still more preferably 70° C. or higher, still more preferably 80° C. or higher, and particularly preferably 90° C. or higher, from the viewpoint of sufficiently shortening the shrinkage time. An upper limit of the temperature of the water is preferably the boiling point or lower.
In the contact step, a method of bringing the raw material fiber into contact with water is not particularly limited. Examples of the method can include a method of immersing the raw material fiber in water, a method of spraying water onto the raw material fiber at room temperature or in a heated steam state, and a method of exposing the raw material fiber to a high humidity environment filled with water vapor. Among these methods, the method of immersing the raw material fiber in water is preferred in the contact step, since the shrinkage time can be effectively shortened and the processing equipment can be simplified.
When the raw material fiber is brought into contact with water in a relaxed state in the contact step, the raw material fiber may be not only shrunk but also be curled to be wavy. In order to prevent the occurrence of curling, for example, the contact step may be performed in a state where the raw material fiber is not relaxed, for example, in a state where the raw material fiber is brought into contact with water while being tensioned in an axial direction of the fiber to the extent that a tension is not applied.
(Drying Step)
The production method of the modified fibroin fiber according to the present embodiment may further include a drying step. The drying step is a step of drying and further shrinking the raw material fiber subjected to the contact step (or the modified fibroin fiber obtained through the contact step) (corresponding to “secondary shrinkage” of
More specifically, the feed roller 42 can be loaded with a wound product of a raw material fiber 36, and the raw material fiber 36 can be continuously and automatically fed from the wound product of the raw material fiber 36 by rotation of an electric motor or the like (not illustrated). The winder 44 can continuously and automatically wind the modified fibroin fiber 38 produced through the contact step and the drying step after being fed out from the feed roller 42 by the rotation of the electric motor (not illustrated). Here, a feed speed of the raw material fiber 36 by the feed roller 42 and a winding speed of the modified fibroin fiber 38 by the winder 44 can be controlled independently of each other.
The water bath 46 and the dryer 48 are arranged between the feed roller 42 and the winder 44 on the upstream side and the downstream side in a feed direction of the raw material fiber 36, respectively. The production apparatus 40 illustrated in
The water bath 46 includes a heater 54, and water 47 heated by the heater 54 is accommodated in the water bath 46. In addition, in the water bath 46, a tension roller 56 is installed in a state of being immersed in the water 47. Accordingly, the raw material fiber 36 fed from the feed roller 42 moves toward the winder 44 while being immersed in the water 47 in a state of being wound around the tension roller 56 in the water bath 46. An immersion time of the raw material fiber 36 in the water 47 is appropriately controlled according to a moving speed of the raw material fiber 36.
The dryer 48 has a pair of hot rollers 58. The pair of hot rollers 58 can be wound with the raw material fiber 36 which is released from the water bath 46 and moves toward the winder 44. Accordingly, the raw material fiber 36 immersed in the water 47 in the water bath 46 is heated by the pair of hot rollers 58 in the dryer 48, dried, and then further fed toward the winder 44.
When the modified fibroin fiber 38 is produced using the production apparatus 40 having such a structure, first, for example, the wound product of the raw material fiber 36 spun using the spinning apparatus 10 illustrated in
Next, the raw material fiber 36 after being into contact with the water 47 (or the modified fibroin fiber 38 produced through contact with the water 47) is heated by the pair of hot rollers 58 of the dryer 48. Accordingly, the raw material fiber 36 after being into contact with the water 47 (or the modified fibroin fiber 38 produced through contact with the water 47) can be dried and further shrunk (corresponding to “secondary shrinkage” of
Instead of the pair of hot rollers 58, the raw material fiber 36 obtained after being into contact with the water 47 may be dried using drying equipment having only a heat source, such as a dry heat plate 64 as illustrated in
As described above, the modified fibroin fiber 38 to be targeted can be automatically, continuously, and extremely easily produced using the production apparatus 40.
More specifically, the processing device 60 illustrated in
The drying device 62 illustrated in
By using the production apparatus having such a structure, the modified fibroin fiber 38 is obtained by shrinking the raw material fiber 36 by the processing device 60, and then, the modified fibroin fiber 38 can be dried by the drying device 62.
The feed roller 42 and the winder 44 may be omitted from the processing device 60 illustrated in
[Shrinking Step by Heating and Relaxation]
The shrinking step of irreversibly shrinking the raw material fiber may be performed by heating and relaxing the raw material fiber. The heating and relaxation of the raw material fiber can be performed by heating the raw material fiber and relaxing and shrinking the heated raw material fiber. Hereinafter, in the shrinkage performed by the heating and relaxation of the raw material fiber, the step of heating the raw material fiber is referred to as a “heating step”, and the step of relaxing and shrinking the heated raw material fiber is referred to as a “relaxation and shrinking step”. The heating step and the relaxation and shrinking step can be performed by, for example, a high temperature heating relaxation device 140 illustrated in
(Heating Step)
In the heating step, the heating temperature of the raw material fiber 36 is preferably equal to or higher than a softening temperature of the modified fibroin used in the raw material fiber 36. In the specification, the softening temperature of the modified fibroin is a temperature at which shrinkage is initiated due to stress relaxation of the raw material fiber 36. In the heating and relaxation shrinking at the temperature equal to or higher than the softening temperature of the modified fibroin, the fiber is shrunk to the extent that it cannot be obtained simply by removing moisture in the fiber. As a result, a residual stress in the fiber generated by drawing in the spinning process can be removed.
An example of a temperature corresponding to the softening temperature can include 180° C. In a case where the heating and relaxation shrinking is performed in a high temperature range of 180° C. or higher, as a relaxation ratio becomes large or the temperature becomes high, the residual stress in the raw material fiber can be more efficiently removed. Accordingly, the heating temperature of the raw material fiber 36 is preferably 180° C. or higher, more preferably 180° C. to 280° C., still more preferably 200° C. to 240° C., and particularly preferably 220° C. to 240° C.
A heating time in the heating step, that is, a retention time in a high temperature heating furnace 143 is preferably 60 seconds or shorter, more preferably 30 seconds or shorter, and still more preferably 5 seconds or shorter, from the viewpoint that elongation of the fiber obtained after the heat treatment is not impaired. It is considered that the length of the heating time does not significantly affect the stress. When the heating time at the heating temperature of 200° C. is 5 seconds or shorter, a deterioration of elongation of the fiber obtained by the heat treatment can be prevented.
(Relaxation and Shrinking Step)
In the relaxation and shrinking step, the relaxation ratio preferably exceeds 1 time, more preferably 1.4 times or more, still more preferably 1.7 times or more, and particularly preferably 2 times or more. The relaxation ratio is a ratio of the feed speed to the winding speed of the raw material fiber 36, and more specifically, a ratio of a feed speed by a feed roller 141 to a winding speed by a winding roller 142.
In the heating and relaxation method performed using the high temperature heating relaxation device 140, the heating step and the relaxation and shrinking step may be separately performed as long as the raw material fiber 36 can be relaxed in a heated state. That is, the heating device may be a device separated from and independent of a relaxation device. In this case, the relaxation device is provided at a subsequence stage of the heating device (the downstream side in the moving direction of the raw material fiber 36) so that the relaxation and shrinking step is performed after the heating step.
The heating and relaxation step may be performed on the raw material fiber separately from the production process of the raw material fiber. That is, the same device as the high temperature heating relaxation device 140 may be provided as an independent device separated from a spinning apparatus 25. A method in which the separately produced raw material fiber 36 is set to the feed roller and the raw material fiber is fed from the feed roller may be adopted. The heating and relaxation step may be performed on one raw material fiber or a plurality of bundled fibers.
[Crosslinking Step]
A crosslinking step of performing chemical crosslinking between polypeptide molecules in the modified fibroin fiber having a shrinkage history of being irreversibly shrunk, which is obtained as described above, or in the raw material fiber before being irreversibly shrunk may be further performed. Examples of a functional group which can be crosslinked can include an amino group, a carboxyl group, a thiol group, and a hydroxyl group. For example, an amino group of a lysine side chain contained in a polypeptide can be crosslinked through an amide bond by dehydration condensation with a carboxyl group of a glutamic acid or asparaginic acid side chain. The crosslinking may be performed by a dehydration condensation reaction under vacuum heating or may be performed using a dehydration condensation agent such as carbodiimide.
The crosslinking between polypeptide molecules may be performed using a crosslinking agent such as carbodiimide or glutaraldehyde or may be performed using an enzyme such as transglutaminase. The carbodiimide is a compound represented by General Formula: R1N═C═NR2 (where R1 and R2 each independently represent an organic group having an alkyl group or cycloalkyl group having 1 to 6 carbon atoms). Specific examples of the carbodiimide can include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N,N′-dicyclohexylcarbodiimide (DCC), 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide, and diisopropyl carbodiimide (DIC). Among them, EDC and DIC are preferred since they have a high ability to form an amide bond between polypeptide molecules and facilitate a crosslinking reaction.
A crosslinking treatment is preferably performed by applying a crosslinking agent to the fiber and performing crosslinking by vacuum heating drying. As the crosslinking agent, a pure product may be applied to the fiber. Alternatively, the crosslinking agent may be applied to the fiber by diluting a pure product with a lower alcohol having 1 to 5 carbon atoms and a buffer or the like to a concentration of 0.005 to 10% by mass. The crosslinking treatment is preferably performed at a temperature of 20 to 45° C. for 3 to 42 hours. By the crosslinking treatment, a higher stress (strength) can be imparted to the fiber.
[Modified Fibroin Fiber]
The modified fibroin fiber according to the present embodiment is a modified fibroin fiber having a shrinkage history of being irreversibly shrunk after spinning. It is preferable that the modified fibroin fiber contains modified fibroin, and a fiber diameter of a raw material fiber before being irreversibly shrunk exceeds 25 μm. Since the modified fibroin fiber according to the present embodiment is obtained by, for example, the production method described above, there is substantially no residual stress generated by drawing during a spinning process.
<Shrinkage Rate>
It is preferable that a shrinkage rate of the modified fibroin fiber according to the present embodiment is 3.3% or less, the shrinkage rate being defined by the following Equation (1):
Shrinkage rate (%)=(1−(length of modified fibroin fiber when dried from wet state/length of modified fibroin fiber when in wet state))×100=(1−(Ldry/Lwet))×100
Shrinkability by contact of the fiber with water can be evaluated using, for example, the shrinkage rate determined by Equation (1) as an index. “Length of modified fibroin fiber when in wet state” and “length of modified fibroin fiber when dried from wet state” can be measured by, for example, the following method.
A plurality of modified fibroin fibers having a length of about 30 cm are bundled to obtain a fiber bundle having a fineness of 150 denier. The fiber bundle is immersed (wetted) in water at 40° C. for 15 minutes, and the immersed fiber bundle is dried at room temperature for 2 hours. After drying, a length of the fiber bundle is measured. Wetting and drying are performed again at least 3 times, an average length during wetting can be used as “length of modified fibroin fiber when in wet state”, and an average length during drying can be used as “length of modified fibroin fiber when dried from wet state”.
In the modified fibroin fiber, it is preferable that such shrinkage is small, and it is particularly preferable that shrinkage of a product such as a fabric formed of a modified fibroin fiber is small.
A shrinkage rate of a fibroin fiber obtained by spinning naturally derived fibroin is generally 11 to 20%, but in the case of the modified fibroin fiber according to the present invention, the fiber diameter of the raw material fiber before being irreversibly shrunk exceeds 25 μm, such that the shrinkage rate by contact with water, that is defined by Equation (1), can be reduced to 3.3% or less.
The shrinkage rate defined by Equation (1) may be 3.2% or less, 3.1% or less, 3.0% or less, 2.9% or less, 2.8% or less, 2.7% or less, 2.6% or less, 2.5% or less, 2.4% or less, 2.3% or less, 2.2% or less, 2.1% or less, 2.0% or less, 1.5% or less, 1.0% or less, or 0.5% or less.
The modified fibroin fiber according to the present embodiment may have various sectional shapes depending on the shape of the spinneret, but the sectional shape of the modified fibroin fiber may be a circular shape or an elliptical shape.
The modified fibroin fiber according to the present embodiment may have a matte-toned appearance or a glossy appearance. A desolvation speed and/or coagulation speed in the spinning process are appropriately adjusted, such that the glossy of the appearance of the fiber can be adjusted. In the present specification, the “matte-toned appearance” means that an appearance is low-gloss.
In addition, the modified fibroin fiber according to the present embodiment may be a modified fibroin fiber containing modified fibroin and having a fiber diameter of more than 25 μm and a shrinkage rate defined by Equation (1) of 3.3% or less. A lower limit of the fiber diameter of the modified fibroin fiber according to the present embodiment preferably exceeds 25 μm, and may be 28 μm or more, 30 μm or more, 32 μm or more, 33 μm or more, more than 33 μm, 34 μm or more, 35 μm or more, 36 μm or more, 38 μm or more, 40 μm or more, 45 μm or more, 50 μm or more, 55 μm or more, or 65 μm or more.
An upper limit of the fiber diameter of the modified fibroin fiber according to the present embodiment is preferably 120 μm or less, and may be 115 μm or less, 110 μm or less, 105 μm or less, 100 μm or less, 95 μm or less, 90 μm or less, 85 μm or less, 80 μm or less, or 75 μm or less. The fiber diameter of the modified fibroin fiber may be more than 25 μm to 120 μm, more than 25 μm to 115 μm, more than 25 μm to 110 μm, more than 25 μm to 105 μm, more than 25 μm to 100 μm, more than 25 μm to 95 μm, more than 25 μm to 90 μm, more than 25 μm to 85 μm, 30 μm to 120 μm, 30 μm to 115 μm, 30 μm to 110 μm, 30 μm to 105 μm, 30 μm to 100 μm, 30 μm to 95 μm, 30 μm to 90 μm, 30 μm to 85 μm, more than 33 μm to 120 μm, 34 μm to 120 μm, 35 μm to 120 μm, 35 μm to 115 μm, 35 μm to 110 μm, 35 μm to 105 μm, 35 μm to 100 μm, 35 μm to 95 μm, 35 μm to 90 μm, 35 μm to 85 μm, 40 μm to 120 μm, 40 μm to 115 μm, 40 μm to 110 μm, 40 μm to 105 μm, 40 μm to 100 μm, 40 μm to 95 μm, 40 μm to 90 μm, 40 μm to 85 μm, 45 μm to 120 μm, 45 μm to 115 μm, 45 μm to 110 μm, 45 μm to 105 μm, 45 μm to 100 μm, 45 μm to 95 μm, 45 μm to 90 μm, 45 μm to 85 μm, 48 μm to 120 μm, 48 μm to 115 μm, 48 μm to 110 μm, 48 μm to 105 μm, 48 μm to 100 μm, 48 μm to 95 μm, 48 μm to 90 μm, 48 μm to 85 μm, 50 μm to 120 μm, 50 μm to 115 μm, 50 μm to 110 μm, 50 μm to 105 μm, 50 μm to 100 μm, 50 μm to 95 μm, 50 μm to 90 μm, 50 μm to 85 μm, 55 μm to 120 μm, 55 μm to 115 μm, 55 μm to 110 μm, 55 μm to 105 μm, 60 μm to 120 μm, 60 μm to 115 μm, 60 μm to 110 μm, 60 μm to 105 μm, 60 μm to 100 μm, 60 μm to 95 μm, 60 μm to 90 μm, 60 μm to 85 μm, 65 μm to 120 μm, 65 μm to 115 μm, 65 μm to 110 μm, 65 μm to 105 μm, 65 μm to 100 μm, 65 μm to 95 μm, 65 μm to 90 μm, 65 μm to 85 μm, 55 μm to 100 μm, 55 μm to 95 μm, 55 μm to 90 μm, 55 μm to 85 μm, 55 μm to 80 μm, or 60 μm to 80 μm. When the fiber diameter exceeds 25 μm, it is possible to sufficiently reduce the shrinkage performed by contact with water. When the fiber diameter is 120 μm or less, it is possible to further increase productivity.
It is preferable that the modified fibroin fiber according to the present embodiment has a small change in fiber diameter before and after the shrinking step of irreversibly shrinking the raw material fiber. Specifically, it is preferable that the modified fibroin fiber has a fiber diameter of less than ±20% of the fiber diameter of the raw material fiber before being irreversibly shrunk. The fiber diameter of the modified fibroin fiber with respect to the fiber diameter of the raw material fiber is preferably less than ±20%, and may be ±19% or less, ±18% or less, ±17% or less, ±16% or less, ±15% or less, less than ±15%, ±12% or less, ±10% or less, less than ±10%, ±5% or less, less than ±5%, ±4% or less, less than ±4%, ±3% or less, less than ±3%, ±2% or less, less than ±2%, ±1% or less, less than ±1%, ±0.9% or less, ±0.8% or less, ±0.7% or less, ±0.7% or less, ±0.6% or less, ±0.5% or less, less than ±0.5%, or ±0.45% or less. The value can be determined by a calculation formula of (fiber diameter of modified fibroin fiber−fiber diameter of raw material fiber)/fiber diameter of raw material fiber×100%.
[Product]
The modified fibroin fiber according to the present embodiment can be applied to a fabric, a knitted fabric, a braided fabric, or a non-woven fabric, and a paper or cotton, as a fiber (a long fiber, a short fiber, a monofilament, a multifilament, or the like) or a yarn (a spun yarn, a twisted yarn, a false twisted yarn, a processed yarn, a blended yarn, a blended spun yarn, or the like). In addition, the modified fibroin fiber can also be applied to high strength applications such as a rope, a surgical suture, a flexible stop for electrical components, and a physiologically active material for implantation (for example, artificial ligament and aortic band). These fibers can be produced based on a known method.
Hereinafter, the present invention will be specifically described based on Examples. However, the present invention is not limited to the following Examples.
[Production of Modified Fibroin]
(1) Preparation of Expression Vector
Modified fibroin having SEQ ID NO: 40 (hereinafter, referred to as “PRT966”), modified fibroin having SEQ ID NO: 15 (hereinafter, referred to as “PRT799”), and modified fibroin having SEQ ID NO: 37 (hereinafter, referred to as “PRT918”) were designed based on a base sequence and an amino acid sequence of fibroin derived from Nephila clavipes (GenBank Accession No.: P46804.1, GI: 1174415). The amino acid sequence set forth in SEQ ID NO: 40 has a sequence obtained by substituting, with VF, all QQs in a sequence obtained by repeating a region of 20 domain sequences present in an amino acid sequence set forth in SEQ ID NO: 7 two times and substituting the remaining Q with I, for the purpose of improving hydrophobicity, and is obtained by adding an amino acid sequence set forth in SEQ ID NO: 11 to the N-terminus. In addition, the amino acid sequence set forth in SEQ ID NO: 15 has an amino acid sequence in which substitution, insertion, and deletion of an amino acid residue for the purpose of improving productivity are performed on the amino acid sequence of the fibroin derived from Nephila clavipes, and is obtained by adding an amino acid sequence (a tag sequence and a hinge sequence) set forth in SEQ ID NO: 12 to the N-terminus.
Subsequently, a nucleic acid encoding the designed modified fibroins PRT966, PRT799, and PRT918 having amino acid sequences set forth in SEQ ID NO: 40, SEQ ID NO: 15, and SEQ ID NO: 37, respectively, was synthesized. In the nucleic acid, an NdeI site was added to the 5′-terminus and an EcoRI site was added to a termination codon downstream. The nucleic acid was cloned with a cloning vector (pUC118). Thereafter, the same nucleic acid was cleaved by restriction enzyme treatment with NdeI and EcoRI, and then recombined into a protein expression vector pET-22b (+) to obtain an expression vector.
(2) Expression of Modified Fibroin
E. coli BLR (DE3) was transformed with the expression vector obtained in (1). The transformed E. coli was cultured in a 2 mL LB medium containing ampicillin for 15 hours. The culture solution was added to a 100 mL seed culture medium containing ampicillin (Table 4) so that OD600 was 0.005. The culture solution temperature was maintained at 30° C., and flask culture was performed until OD600 reached 5 (for about 15 hours) to obtain a seed culture solution.
The seed culture solution was added to a jar fermenter to which a 500 mL production medium (Table 5) was added so that OD600 was 0.05. The culture was performed while maintaining the culture solution temperature at 37° C. and constantly controlling the pH to 6.9. In addition, a dissolved oxygen concentration in the culture solution was set to be maintained at 20% of a dissolved oxygen saturation concentration.
Immediately after glucose in the production medium was completely consumed, a feed solution (glucose 455 g/l L, Yeast Extract 120 g/l L) was added at a rate of 1 mL/min. The culture was performed while maintaining the culture solution temperature at 37° C. and constantly controlling the pH to 6.9. In addition, the culture was performed for 20 hours so that a dissolved oxygen concentration in the culture solution was set to be maintained at 20% of a dissolved oxygen saturation concentration. Thereafter, 1 M isopropyl-β-thiogalactopyranoside (IPTG) was added to the culture solution so that the final concentration was 1 mM to induce expression of the modified fibroin. 20 hours after the addition of IPTG, the culture solution was centrifuged to collect fungus bodies. SDS-PAGE was performed by using fungus bodies prepared from the culture solution before the addition of IPTG and the culture solution after the addition of IPTG, and expression of the modified fibroin to be targeted was confirmed by appearance of a band with a size of the modified fibroin to be targeted depending on the addition of IPTG.
(3) Purification of Modified Fibroin
2 hours after the addition of IPTG, the collected fungus bodies were washed with a 20 mM Tris-HCl buffer (pH 7.4). The washed fungus bodies were suspended in a 20 mM Tris-HCl buffer (pH 7.4) containing approximately 1 mM PMSF, and cells were disrupted in a high-pressure homogenizer (manufactured by GEA Niro Soavi Technologies). The disrupted cells were centrifuged to obtain a precipitate. The obtained precipitate was washed with a 20 mM Tris-HCl buffer (pH 7.4) until the purity was high. The washed precipitate was suspended in an 8 M guanidine buffer (8 M guanidine hydrochloride, 10 mM sodium dihydrogen phosphate, 20 mM NaCl, and 1 mM Tris-HCl, pH 7.0) so that a concentration thereof was 100 mg/mL, and the suspended precipitate was dissolved by performing stirring using a stirrer at 60° C. for 30 minutes. After dissolution, the resultant product was dialyzed with water by using a dialysis tube (cellulose tube 36/32 manufactured by Sanko Junyaku Co., Ltd.). A white coagulation protein obtained after dialysis was collected by centrifugation, and water was removed in a freeze dryer to recover freeze-dried powder, thereby obtaining modified fibroins (PRT966, PRT799, and PRT918).
[Production of Raw Material Fiber]
(1) Preparation of Dope Solution
Dimethyl sulfoxide (DMSO) in which 4.0% by mass of LiCl was dissolved was prepared as a solvent for dissolution, and 26% by mass of the modified fibroin (PRT966) obtained in the production process of the modified fibroin was mixed with DMSO, and the modified fibroin was dissolved by heating the mixture with an aluminum block heater at 90° C. for 1 hour while performing stirring. Filtration was performed with a metal filter having a mesh size of 1 μm and defoaming was performed, thereby preparing a dope solution.
(2) Dry Wet Spinning
The prepared dope solution was added in a reserve tank and discharged from a monohole nozzle having a diameter of 0.3 mm into a coagulation bath containing 100% by mass of methanol using a gear pump to coagulate the dope solution using the spinning apparatus of
Extrusion nozzle diameter: 0.3 mm
Temperature of coagulant liquid: 5° C.
Draw ratio in water washing bath: 2.0 to 6.0 times
Temperature of water washing bath: 40° C.
Dry temperature: 60° C.
[Evaluation of Fiber Diameter of Raw Material Fiber]
A diameter of the raw material fiber obtained in (2) was calculated using an optical microscope. The results are shown in Table 6. A measured value was an average value of the number of samples (n=5).
[Production of Modified Fibroin Fiber]
(1) Shrinking Step (Contact Step and Drying Step)
The raw material fiber obtained in (2) was immersed and shrunk in water at 40° C. using the spinning apparatus of
(2) Evaluations of Cross-Sectional Shape and Appearance of Modified Fibroin Fiber
(3) Evaluation of Shrinkability of Modified Fibroin Fiber
A plurality of modified fibroin fibers obtained in (1) were aligned and bundled to a length of about 30 cm to obtain a fiber bundle having a fineness of 150 denier. The fiber bundle was immersed (wetted) in water at 40° C. for 15 minutes, and the immersed fiber bundle was dried at room temperature for 2 hours. After drying, a length of the fiber bundle was measured. Wetting and drying were performed again at least 3 times, an average length during wetting was set as a length of the modified fibroin fiber when in a wet state (Lwet), and an average length during drying was set as a length of the modified fibroin fiber when dried from the wet state (Ldry), and then, a shrinkage rate was calculated according to the following equation. A measured value was an average value of the number of samples (n=3).
Equation: shrinkage rate (%)=(1−(Ldry/Lwet))×100
The shrinkage rate of the modified fibroin fiber in each of the fiber diameters is shown in Table 6. As a reference value, a relative value when a value of the shrinkage rate of the modified fibroin fiber of Comparative Example 1 is 100 is also shown in Table 6.
As shown in Table 6, in each of the modified fibroin fibers having a fiber diameter of more than 25 μm (Examples 1 to 5), the shrinkage rate was lower than that of the modified fibroin fiber having a fiber diameter of less than 25 μm (Comparative Example), and shrinkability to water was reduced. In addition, in each of the modified fibroin fibers having a fiber diameter of 61 μm to 81 μm (Examples 2 and 3), the effect of reducing shrinkability to water was maximized. In addition, the fiber diameter of the modified fibroin fiber to the fiber diameter of the raw material fiber was 0.41% at the maximum and −0.02% at the minimum, which showed that extremely excellent dimensional stability was obtained.
The freeze-dried powder of the modified fibroin (PRT799) was added to a dimethyl sulfoxide solution of lithium chloride (concentration: 4.0% by mass) to a concentration of 24% by mass, and the freeze-dried powder was dissolved by performing mixing using a shaker for 3 hours. Thereafter, an insoluble matter and bubbles were removed to obtain a modified fibroin solution (spinning raw material solution).
The obtained spinning raw material solution was heated to 90° C., filtration was performed with a metal filter having a mesh size of 5 μm, the spinning raw material solution was left to stand in a 30 mL stainless steel syringe, defoaming was performed, and then, the spinning raw material solution was discharged from a solid nozzle having a needle diameter of 0.2 mm into a coagulation bath containing 100% by mass of methanol. A discharge temperature was 90° C. After coagulation, the obtained raw yarn was wound and naturally dried to obtain a modified fibroin fiber (raw material fiber).
A circular knitted fabric (thickness: 180 denier, gauge number: 18) was produced using a circular knitting machine and using a twist yarn obtained by twisting the raw material fiber. 20 g of the obtained knitted fabric was cut out and used as a test piece.
The combustibility test was performed based on “Test method for powdery or low melting point synthesis resin” described in “Fire Fighting Hazards No. 50 (May 31, 1995)”. The test was performed under conditions of a temperature of 22° C., a relative humidity of 45%, and an atmospheric pressure of 1,021 hPa. The measurement results (oxygen concentration (%), combustion rate (%), and converted combustion rate (%)) are shown in Table 7.
As a result of the combustibility test, a limit oxygen index (LOI) value of the knitted fabric knitted with the modified fibroin (PRT799) fiber was 27.2. In general, it is known that the knitted fabric is flame retardant when the LOI value is 26 or more. It can be seen that the modified fibroin is excellent in flame retardancy.
The freeze-dried powder of the modified fibroin was added to a dimethyl sulfoxide solution of lithium chloride (concentration: 4.0% by mass) to a concentration of 24% by mass, and the freeze-dried powder was dissolved by performing mixing using a shaker for 3 hours. Thereafter, an insoluble matter and bubbles were removed to obtain a modified fibroin solution (spinning raw material solution).
The obtained spinning raw material solution was heated to 60° C., filtration was performed with a metal filter having a mesh size of 5 μm, the spinning raw material solution was left to stand in a 30 mL stainless steel syringe, defoaming was performed, and then, the spinning raw material solution was discharged from a solid nozzle having a needle diameter of 0.2 mm into a coagulation bath containing 100% by mass of methanol. A discharge temperature was 60° C. After coagulation, the obtained raw yarn was wound and naturally dried to obtain a modified fibroin fiber (raw material fiber).
For comparison, a commercially available wool fiber, a cotton fiber, a tencel fiber, a rayon fiber, and a polyester fiber were prepared as the raw material fibers.
A flat knitted fabric was produced using a flat knitting machine using each raw material fiber. Table 8 shows thicknesses and gauge numbers of the knitted fabrics obtained by using the PRT918 fiber and the PRT799 fiber. Thicknesses and gauge numbers of the knitted fabrics obtained by using other raw material fibers were adjusted so as to have almost same coverage factor as that of the knitted fabric made of the modified fibroin fiber. The details are as follows.
Two knitted fabrics cut into 10 cm×10 cm were combined and four sides were sewed to obtain a test piece (sample). The test piece was left to stand in a low humidity environment (temperature 20±2° C. and relative humidity 40±5%) for 4 hours or longer, the test piece was transferred to a high humidity environment (temperature 20±2° C. and relative humidity 90±5%), and then, the temperature was measured at an interval of 1 minute for 30 minutes with a temperature sensor attached to the center of the inside of the test piece.
From the measurement results, the maximum hygroscopic and exothermic degree was determined according to the following Equation A.
maximum hygroscopic and exothermic degree={(maximum value of sample temperature when sample is placed under low humidity environment until sample temperature reaches equilibrium and then transferred to high humidity environment)−(sample temperature when sample is placed under low humidity environment until sample temperature reaches equilibrium and then transferred to high humidity environment)}(° C.)/sample weight (g) Equation A:
Calculation results of the maximum hygroscopic and exothermic degrees of the knitted fabrics are shown in Table 9.
As shown in Table 9, it could be seen that in the modified fibroins (PRT918 and PRT799), the maximum hygroscopic and exothermic degrees were high and the hygroscopic and exothermic properties were excellent, as compared with existing materials.
The freeze-dried powder of the modified fibroin was added to a dimethyl sulfoxide solution of lithium chloride (concentration: 4.0% by mass) to a concentration of 24% by mass, and the freeze-dried powder was dissolved by performing mixing using a shaker for 3 hours. Thereafter, an insoluble matter and bubbles were removed to obtain a modified fibroin solution (spinning raw material solution).
The obtained spinning raw material solution was heated to 60° C., filtration was performed with a metal filter having a mesh size of 5 μm, the spinning raw material solution was left to stand in a 30 mL stainless steel syringe, defoaming was performed, and then, the spinning raw material solution was discharged from a solid nozzle having a needle diameter of 0.2 mm into a coagulation bath containing 100% by mass of methanol. A discharge temperature was 60° C. After coagulation, the obtained raw yarn was wound and naturally dried to obtain a modified fibroin fiber (raw material fiber).
For comparison, a commercially available wool fiber, a silk fiber, a cotton fiber, a rayon fiber, and a polyester fiber were prepared as the raw material fibers.
A flat knitted fabric was produced using a flat knitting machine using each raw material fiber. A count, number of twists, gauge number, and basis weight of the knitted fabric obtained by using the PRT966 fiber or the PRT799 fiber are shown in Table 10. The knitted fabrics obtained by using other raw material fibers were adjusted so as to have almost same coverage factor as that of the knitted fabric made of the modified fibroin fiber. The details are as follows.
The heat retaining properties were evaluated using a KES-F7 Thermo Lab II tester manufactured by Kato Tech Co., Ltd. and using a dry contact method (a method assuming that skin is in direct contact with cloth in a dry state). One knitted fabric cut into a rectangle of 20 cm×20 cm was used as a test piece (sample). The test piece was set to a heat plate set to a constant temperature (30° C.), and the amount of heat (a) dissipated through the test piece was calculated under a condition of a wind speed of 30 cm/sec in a wind tunnel. The amount of heat (b) dissipated under the same condition as above was calculated without setting the test piece, and a heat retention rate (%) was calculated according to the following Equation B.
Equation B: heat retention rate (%)=(1−a/b)×100
From the measurement results, a heat retention index was determined according to the following Equation C.
Equation C: heat retention index=heat retention rate (%)/basis weight (g/m2) of sample
The calculation results of the heat retention index are shown in Table 11. As the heat retention index is higher, it can be evaluated as a material having excellent heat retention properties.
As shown in Table 11, it could be seen that in the modified fibroins (PRT966 and PRT799), the heat retention indices were high and the heat retention properties were excellent, as compared with existing materials.
As shown in Reference Examples 1 to 3, when the modified fibroin is modified spider silk fibroin, the heat retention properties, the hygroscopic and exothermic properties, and/or the flame retardancy can be more excellent. When the modified spider silk fibroin is used for the fiber of the present invention, the heat retention properties, the hygroscopic and exothermic properties, and/or the flame retardancy can be more excellent, and thus, a fiber having a reduced shrinkage rate to water can be obtained.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2018-185300 | Sep 2018 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2019/038428 | 9/27/2019 | WO | 00 |
